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Abstract
DESIGNING MULTI-LAYERED NANOPARTICLES FOR COMBINATION GENE
AND DRUG CANCER THERAPY. 1Asiri S. Ediriwickrema, 2Jiangbing Zhou,
3Mark Saltzman. (Sponsored by Dr. Joseph Piepmeier and Dr. Abhijit Patel).
1Yale University School of Medicine, New Haven, CT. 2Department of
Neurosurgery, Yale University School of Medicine, New Haven, CT. 3Department
of Biomedical Engineering, Yale University, New Haven, CT.
Cancer continues to be a highly prevalent and lethal disease, despite
significant advances in understanding tumor biology and developing new
chemotherapies. Major obstacles in cancer chemotherapy are drug resistance
and systemic toxicities. Potential strategies for addressing these problems
include delivering combination therapies to overcome drug resistance, and
utilizing synergistic agents to minimize dosing and subsequently drug toxicity. In
turn, delivery can also be optimized to target the tumor site and consequently
minimize systemic side effects. Polymer nanocarriers are gaining interest as
vehicles for cancer therapeutics for their abilities to not only deliver multiple
agents, but also target the tumor itself. Our goal is to design multi-layered
polymer nanoparticles (MLNPs) for efficient delivery of small molecules and
genetic material towards synergistically inhibiting tumor growth. The MLNPs were
first optimized for transfection in vitro through delivery of plasmids encoding for
luciferase (pLuc) and green fluorescent protein (pGFP). The particles were then
evaluated for effective delivery of both a candidate small molecule, camptothecin
(CPT), and a plasmid encoding for TNF related apoptosis inducing ligand
(pTRAIL) (CT MLNPs). Co-delivery of CPT and pTRAIL via CT MLNPs were then
evaluated for growth inhibition of brain, colorectal, and breast cancer cells in
vitro. MLNPs were approximately 116 nm in diameter. They were able to delivery
approximately 575 ng of plasmid per mg of particle, and between 0.1 mg to 0.01
µg of CPT per mg of particle. MLNPs were non-toxic, and human embryonic
kidney cells (293T) transfected with pLuc loaded MLNPs expressed comparable
amounts of luciferase as cells transfected with the gold standard lipid formulation,
Lipofectamine 2000. Thirty-seven percent of transfected 293T cells expressed
GFP 72 h after transfection. Studies on tumor death kinetics related to CPT
exposure and pTRAIL transfection suggested that simultaneous transfection and
drug exposure provided the greatest inhibition of cell growth. MLNPs were able
to provide the optimal timing for delivery of both agents. Synergy analysis of codelivering CPT and pTRAIL via CT MLNPs, using the Chou-Talalay method,
provided a combination index at 50% inhibition ranging between 0.31 and 0.53
for all cell lines. These CI values indicate a synergistic interaction between the
two agents. For obtaining a 50% effect level, co-delivery with MLNPs resulted in
providing 3.14-7.38 fold reduction in CPT and 4.66 to 6.09 fold reduction in
pTRAIL. These initial results support our hypothesis that MLNPs can deliver both
small molecule and genetic agents towards synergistically inhibiting tumor
growth.
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1 Introduction
1.1

History of advancements in cancer therapy.
The oldest documented case of cancer occurred in Egypt around 3000 BC.

The record details eight cases of tumors involving the breasts, and ominously
describes the disease as having no treatment1. Although surgical resections
have been utilized since 1600 BC as a treatment modality, it was only in the mid
nineteenth century, with the advent of anesthesia, that modern tumor resections
were utilized for cancer therapy. The improved techniques allowed for more facile
resections and better outcomes. Emil Grubbe, a Chicago medical student, first
used X-rays to kill cancer cells in 1896. Surgical and radiotherapy continued to
be the mainstay of treatment until 1948 when Sidney Faber, a pathologist in
Boston, used an antifolate compound in children with leukemia2,3. Farber was
able to induce remission, although transient, in his first patient, and consequently
pioneered the field of cancer chemotherapy.
The ensuing decades have since generated numerous advances in cancer
biology and chemotherapy. The evaluation of the biochemical processes involved
in drug resistance made considerable strides in the 1960s, and resulted in the
implementation of combination chemotherapies in 1965 and adjuvant
chemotherapy in 19723. The National Cancer Institute began increasing support
of molecular cancer biology in the 1970s and 1980s, which was rewarded by the
discovery of the first oncogenes in humans in 1976 and the identification of the
critical role of TP53 in cancer development in 19894,5. Significant improvements
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in cancer mortality were first noticeable in the 1990s, and the field of targeted
cancer therapies blossomed with new discoveries in cancer signaling pathways
involved in tumor development, proliferation, and metastasis. Identification of
novel targets enabled the discovery of targeted therapies including Imatinib, a
tyrosine kinase inhibitor, in 1992, and Trastuzumab, a targeted monoclonal
antibodies for HER2 positive breast cancer in 19983.
Further, the completion of the Human Genome Project in 2003, a historical
point in the field of genetics and overall scientific exploration, allowed for
revolutionary advances in understanding many human diseases including
cancer. Multiple international projects, like The Cancer Genome Atlas, were
initiated to analyze the genetics of multiple cancer subtypes. Through extensive
genome analysis of tissues from several patients, researchers are gaining a
stronger understanding of the development, susceptibilities, and prognosis of
individual cancers, and in turn learning how to design patient specific therapies.
Consequently, the death rates for common cancers, like prostate, breast, lung,
and colorectal, continue to decline with the development of new small molecules
and immunotherapies, target specific screens, and novel combination therapies.
In 2003, the five year survival for cancers from all sites has increased to 66.7
percent. Despite these promising advances in cancer therapy, it is still the
second leading cause of death in the United States. There are over 1.6 million
new cases annually, and approximately 580,000 deaths each year6. These
numbers will likely increase due to the continued aging of the population. Even
as cancer survivors live longer, they are at a higher risk for developing new
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malignancies. Further, the issue of drug resistance and tumor recurrence
continue to hinder cancer therapies, and more investigation is required to
overcome these obstacles.
1.2

Cancer biology, drug resistance, and rational therapeutic design.
The birth of scientific oncology ensued when Rudolf Virchow examined

blood samples from leukemia patients under the microscope in 1847. Currently,
cancer pathogenesis is considered a complex multistep process where cells
attain certain hallmark properties through both genetic and epigenetic
alterations7,8. Carcinogenesis is primarily a consequence of changes in the
genetic code or gene expression. The affected genes can be categorized into
three main groups: oncogenes, tumor suppressor genes, and mismatch-repair
genes. Changes in gene expression may in turn allow cells to maintain
proliferative signaling, evade growth suppressive signals, resist cell death,
promote invasion and metastasis, confer replicative immortality, deregulate
cellular energetics, promote genomic instability, and initiate angiogenesis9.
Additionally, tumor interactions with adjacent stroma and the immune system can
promote proliferation and metastasis through avoiding immune destruction and
stimulating tumorigenic inflammation. The multiple, interconnected pathways
complicates efforts for providing effective therapies. Therefore, a paradigm shift
is underway as researchers are working to analyze individual tumors in order to
design therapies for specific cancer phenotypes.
Additionally, epigenetic factors can promote carcinogenesis without directly
conferring any genotypic variations. Deoxyribonucleic acid (DNA) methylation,
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histone modification, and gene silencing are interesting epigenetic events
involved in cancer pathogenesis10. New therapies have been produced to modify
histone acetylation, which can consequently alter gene expression11. Further, the
field of the RNA interference (RNAi), through small interfering RNAs (siRNA) or
microRNAs (miRNA) delivery, has expanded significantly, and can potentially be
utilized to silence any gene of interest12,13.
Evaluating the steps involved in cancer pathogenesis has in turn allowed for
the development of more effective therapies. For instance, cancer cells can
develop increased proliferative signaling by up-regulating surface growth factor
receptors like EGFR. Researchers have translated these discoveries into
promising clinical therapies by developing EGFR specific inhibitors. Similarly, by
analyzing the specific hallmarks necessary for cancer progression, new pipelines
of therapeutics are being developed to treat the disease. Table 1 describes the
multiple hallmarks of cancer pathogenesis, respective cellular and molecular
alterations, and associated targeted therapies7,14,15. Through extensive molecular
and genetic analysis, physicians are better equipped to detect, classify, monitor,
and ultimately treat cancer. However, the difficulty in designing adequate
therapies is becoming increasingly clear as we begin to understand the
intricacies of cancer biology and the vast heterogeneity of tumors.
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Table 1: Hallmarks of cancer pathogenesis and therapeutic
implications7,14,15.
HALLMARK OF CANCER

CELLULAR AND MOLECULAR

TARGETED

PATHOGENESIS

ALTERATIONS

THERAPIES

1. SUSTAINING

↑ MAP-kinase pathway, ↑ PI3-kinase

EGFR inhibitors

PROLIFERATIVE

pathway, ↓ PTEN, mTOR kinase pathway

SIGNALING
2. EVADING GROWTH

↓ TP53, ↓ RB, ↓ NF2, ↓ LKB1, TGF-β

Cyclin-dependent

SUPPRESSORS

signaling

kinase inhibitors

3. AVOIDING IMMUNE

↓ CTLs, ↓ CD4+ Th1 cells, ↓ NK cells, ↑

Immune activating

DESTRUCTION

Tregs, ↑ MDSCs, TGF-β signaling

anti-CTLA4 mAb,
ex-vivo T cell
modifications

4. ENABLING

↑ Telomerase, ↓ TP53

REPLICATIVE

Telomerase
inhibitors

IMMORTALITY
5. TUMOR PROMOTING

B lymphocytes, macrophages, mast cells,

Selective anti-

INFLAMMATION

myeloids progenitors, necrosis,

inflammatory drugs

neutrophils, T lymphocytes, ↑ IL-1α, ↑
reactive oxygen species
6. ACTIVATING

↑ CCL5/RANTES, ↑ c-Met, ↑ CSF1, ↑

Inhibitors of HGF/c-

INVASION AND

CCPs, ↑ heparanase, ↑ EMT, ↑ IL-4, ↑

Met

METASTASIS

matrix-degrading enzymes, ↑ N-cadherin,
↑ Wnt signaling, ↓ E-cadherin, Snail, Slug,
TGF-β signaling, Twist, Zeb1/2,
macrophages, neoplastic stroma
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7. INDUCING

↑ FGF family proteins, ↑ Ras, ↑ Myc, ↑

Inhibitors of VEGF

ANGIOGENESIS

VEGFa, ↓ endostatin, ↓ plasmin, TGF-β

signaling

signaling, ↓ TSP-1, endothelial cells
↓ BRCA, ↓ TP53

PARP inhibitors

9. RESISTING CELL

↑ A1, ↑ Bcl-2, ↑ Bcl-xL, ↑ Bcl-w, ↑ Mcl-1, ↑

Proapoptotic BH3

DEATH

extrinsic growth factor signaling, ↓ Bax, ↓

mimetics, Bcl-2

Bak, ↓ BH3 proteins, ↓ TP53, ↓ extrinsic

antagonists, TRAIL

ligand-induced death pathways

therapy

↑ GLUT1, ↑ HIF, ↑ IDH1/2

Aerobic glycolysis

8. GENOME INSTABILITY
AND MUTATION

10. DEREGULATING
CELLULAR ENERGETICS
11. DEREGULATING

inhibitors
Beclin

AUTOPHAGY

Autophagy
inhibitors

12. TUMOR

Cancer stem cells, endothelial cells (notch,

Anti-stem cell

MICROENVIRONMENT

neuropilin, Robo, and Eph-A/B singaling),

antibodies, PDFG

fibroblasts, myofibroblasts, neoplastic

receptor inhibition

stroma, pericytes, TGF-β signaling

Bax - Bcl-2-associated X, Bcl - B-cell lymphoma, BRCA – breast cancer, CCL5/RANTES Chemokine (C-C motif) ligand 5/ regulated on activation, normal T cell expressed and secreted,
CCPs - cysteine cathepsin proteases, CD4 – cluster of differentiation 4, CSF – colony-stimulating
factor, CTL - CD8+ cytotoxic T lymphocytes, EMT - epithelial-mesenchymal transition, EPH –
ephrin type, FGF - fibroblast growth factor, GLUT – glucose transporter, HGF – hepatocyte
growth factor, HIF – hypoxia-inducible factor, IDH - isocitrate dehydrogenase, IL – interleukin,
LKB1 – liver kinase B1, MAP – mitogen-activated protein, MCL – myeloid cell leukemia, MDSCs myeloid-derived suppressor cells, mTOR – mammalian target of rapamycin, NF2 – neurofibromin
2 (merlin), NK – natural killer, PI3 - Phosphatidylinositide 3, PTEN – phosphatase and tensin
homolog, RB – retinoblastoma, Robo – roundabout, TGF – transforming growth factor, Th – T
helper, Tregs - regulatory T cells, TSP – thrombospondin, VEGF – vascular endothelial growth
factor, ZEB - Zinc finger E-box-binding homeobox.

Despite our increasing knowledge of cancer pathogenesis, the disease
process remains extremely complex. Every cell lineage in the body can be
affected. Inherent genomic instability and biological diversity in cancer cells can

7
lead to treatment resistance. Only a small fraction of tumor cells is highly
sensitive to therapy, and even they can develop resistance and progress into a
more aggressive disease. Drug resistance can be either intrinsic or acquired.
Intrinsic resistance describes tumor cells that have decreased or no sensitivity to
therapeutic agents. Cells can develop resistance through a variety of
mechanisms including decreased drug uptake, up-regulation of drug efflux
transporters, aberrant cell cycle checkpoints, increase in DNA repair, increased
drug metabolism, induction of stress response genes, and inhibition of
apoptosis16. Additionally, individual cells can be resistant through its own unique
variation, which further complicates cancer therapies. Acquired resistance refers
to neoplasms that were initially responsive to certain therapies becoming
unresponsive. Similar to the development of bacterial resistance to antibiotics,
chemotherapeutics can select for inherently resistant tumor cells. Due to the
characteristic genomic instability of many cancer subtypes and the mutagenic
properties of chemotherapeutic interventions, new mutations can readily lead to
the development of drug resistance. Of note, hierarchies in signaling cascades
involved in tumor development, can diminish efficacy of targeted therapies, if the
new mutation overrides the targeted factor in the signaling cascade. For
instance, mutations in the tumor suppressor gene, PTEN, can decrease efficacy
of anti-HER2 immunotherapy, or inactivation of TP53 can minimize the
cytotoxicity of several cancer therapies17. Mutations and natural selection are
fundamental in the development of resistance, as they are the primary drivers of
cancer pathogenesis.
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The two overarching models of carcinogenesis are the stochastic clonal
evolution model and the hierarchal cancer stem cell model18. The original
stochastic model describes tumor pathogenesis as the progression of somatic
mutations that lead to isolation of a dominant cancerous clone that, through
selective influences, eventually progresses into metastatic tumors. However,
during the past two decades, studies have shown that certain cancer types arise
from a more hierarchal organization of cells. These tumors are comprised of
multiple cell subpopulations having a spectrum of proliferative and regenerative
capabilities. Bonnet and Dick first described this phenomenon in human acute
myeloid leukemia cells19. They isolated rare leukemia initiating cells that have
differentiate and proliferative capabilities similar to leukemic stem cells, and
demonstrated that these cells are responsible for the regenerative, selfperpetuating, and diverse nature of the tumor. The primitive tumor initiating cells
are inherently quiescent and less susceptible to traditional therapeutics that
target rapidly proliferating tumor cells18,20. Subsequent studies have identified
tumor initiating cells in breast cancer21,22, colon cancer23-25, melanoma26, and
brain cancer27-29. Therefore, effective therapies will require targeting of these rare
initiating cells since traditional chemotherapies target only the proliferative subset
of the cancer.
In addition to tumor biology, multiple host factors influence efficacy of
current chemotherapies. Decreased absorption, rapid metabolism, and increased
clearance can decrease serum drug concentrations. Delivery to the tumor can be
impaired in large, necrotic malignancies. Additionally, drug solubility and size can

9
also hinder tumor delivery and penetration. The tumor microenvironment,
including both the abnormal vasculature and adjacent stromal cells, can impede
drug delivery or increase drug clearance. Patients also have variable capacities
to tolerate chemotherapeutics, and the development of certain side effects can
significantly obstruct dosing and treatment duration16.
1.3

Strategies to improve cancer therapies and implications in personalized
medicine.
With the discovery of numerous clinically relevant cancer genes, new efforts

are being implemented to streamline evaluation of cancer genomes towards
ultimately translating to personalized, clinical therapies 30. Improvements in
sequencing technologies have evolved into new paradigms for analyzing tumor
specimens. Massively parallel screens can examine patient samples for
potentially actionable targets30-32. Further, a pilot program, the Master Protocol,
was recently approved by the Food and Drug Administration (FDA), and will
connect patients to relevant drug therapy trials based on biomarkers33.
Determining specific gene or biomarker expression profiles can align specific
disease with the ideal, patient centered treatment regimen.
Due to tumor heterogeneity and the development of drug resistance, future
therapeutic regimens will likely incorporate combination therapies. Bozic et al.
described a mathematical model that evaluates tumor response to targeted
monotherapy and combination therapies34. Dual therapy was often adequate for
long-term disease control, and patients with a larger initial disease burden may
require triple therapy. Additionally, simultaneous therapy was more effective than
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sequential therapy. As the spectrum of genomic targets or abnormal signaling
cascades widens, it is becoming increasingly difficult to develop targeted small
molecules or immunotherapies. Gene therapy can potentially address that issue,
since it has the potential to alter expression of any gene of interest. However,
gene delivery can be either inefficient or dangerous. Similarly, the multiple
clinically available chemotherapeutics are highly toxic, especially with systemic
delivery. Commonly used cytotoxic agents can act indiscriminately against both
cancerous and healthy cells resulting in nausea and hair loss to more serious
toxicities, including neutropenia, peripheral neuropathies, kidney failure,
encephalopathy, and heart disease35. The associated side effects of common
chemotherapeutics, as well as host factors and systemic delivery barriers can
severely limit dosing and, ultimately, treatment efficacy. Current research in
nanoparticle drug delivery is addressing these issues, and has made several
promising advancements for efficient delivery of both chemotherapeutic drugs
and gene therapy.
1.4

Nanoparticles and their applications in drug and gene delivery.

1.4.1 Introduction to nanomedicine.
Medical nanotechnology, or nanomedicine, is rapidly gaining interest in the
field of oncology. The National Cancer Institute (NCI) Alliance for
Nanotechnology in Cancer is currently supporting nine multi-disciplinary research
and development centers, twelve nanotechnology platform partnerships, and six
training centers nationwide. The NCI’s Nanotechnology Plan includes six areas
of interest, including the design of multifunctional therapeutics towards
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addressing critical issues in drug delivery such as improving drug solubility and
stability, prolonging drug half-lives in plasma, minimizing off target effects, and
concentrating drugs at the target site36. Nanotechnology is traditionally defined as
sub-micron sized molecular devices or nanoparticles predominantly ranging from
5 nm to 500 nm in at least one dimension. There continues to be significant
efforts in designing methods to incorporate therapeutic agents into biocompatible
nanodevices including polymer nanoparticles, liposomes, micellar systems,
inorganic nanoparticles, nanotubes, and dendrimers. Table 2 lists a few
examples of nanoparticle therapeutics that are currently approved by the FDA or
in clinical trials. For reference, Figure 1 compares various nanoparticles to
common biological structures including hemoglobin, which is approximately 5 nm
is size, to the human pupil, which ranges from 4-9 mm. Nanovectors for drug
delivery typically contain a core material or matrix, a therapeutic payload, and
surface modifications. Of interest are polymer nanoparticles, which have been
studied extensively during the previous few decades.
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Table 2: Examples of nanoparticle therapeutics37-39.
NANOCARRIER
INORGANIC
NANOPARTICLE

NAME
Ferumoxide

FORMULATION
Iron oxide MRI
contrast agent

INDICATION
Liver imaging

STATUS
Approved
1996

CYT-6091

TNFα-PEG-gold

Solid tumors

Phase I

LIPOSOME

Doxil

Liposomal doxorubicin

PROTEIN
NANOPARTICLE

Abraxane

Paclitaxel-albumin

Ovarian, breast
cancer
Metastatic
breast cancer

Approved
1995
Approved
2005

POLYMERIC MICELLE

GenexolPM

Miceller paclitaxel

Phase IIIII

POLYMER-DRUG
CONJUGATE

Xyotax

Paclitaxel-poly-Lglutamic acid

Breast, lung,
pancreatic
cancer
Breast, ovarian
cancer

POLYMER
NANOPARTICLE

BIND-014

Docetaxel-PLGA/PLAPEG

Phase II

SEL-068

Nicotine-tSVPTM

Non-small cell
lung cancer,
prostate cancer
Nicotine
addiction

RADIOIMMUNOCONJUGATE

Phase II

Phase I

Zevalin

Anti-CD20 conjugated
Non-Hodgkin’s Approved
to yttrium-90 or indium- lymphoma
2002
111
PEG – polyethylene glycol, PLA – Polylactic acid, PLGA - poly(lactic-co-glycolic) acid, TNF –
tumor necrosis factor, tSVPTM – targeted Synthetic Vaccine Particle.

Figure 1: Relative sizes of nanoparticles compared to common biological
structures.
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1.4.2 Drug encapsulated polymer nanoparticle pharmacokinetics.
Langer et al40 first described a method for incorporating proteins and
macromolecules into polymers in 1976. The field of polymer drug delivery has
continued to evolve and generate an array of novel applications41,42. Many
polymers are safe to use clinically, and the most extensively studied is
poly(lactic-co-glycolic acid) (PLGA), which was approved by the FDA in 1969.
PLGA nanoparticles are being formulated to target specific tumors and deliver a
host of agents including chemotherapeutics or RNAi43-45. Upon exposure to
physiologic solutions, PLGA undergoes hydrolysis into biocompatible
metabolites, glycolic acid (GA) and lactic acid (LA), which are eventually
metabolized through the citric acid cycle(Figure 2). Biodegradable, polymer
nanoparticles provide several distinct advantages as a drug delivery vector
including tunable payload release characteristics and superior pharmacokinetics.

Figure 2: Hydrolysis of poly(lactic-co-glycolic) acid.
These properties are most apparent when delivering lipophilic or rapidly
degradable agents. The majority of clinically available chemotherapeutic agents
are lipophilic. A common measurement of lipophilicity is the distribution
coefficient, log(D), where D is the ratio of solute concentration in octanol to the
solute concentration in aqueous buffer in both ionized and non-ionized forms.
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Log(D) values larger than zero indicate greater solute partitioning into the
hydrophobic solvent relative to water46. Figure 3 illustrates the spectrum of
distribution coefficients at physiologic conditions for currently approved antineoplastic agents, and Table 3 lists the specific values for individual agents. The
PLGA matrix releases encapsulated drugs at a sustained rate, allowing for both
solubilization of drugs within the intravascular space, and zero order release
kinetics. When compared to repeat free drug boluses, zero order release kinetics
are more amenable for delivering drug concentrations within the therapeutic
window. Free drug boluses result in pulsatile plasma concentrations. Levels
above the minimal tolerated concentration may result in serious toxicity, and
levels below the minimum effective concentration will be sub-therapeutic(Figure
4). The ratio of LA to GA subunits can be adjusted to tune the rate of drug
release, allowing for release profiles ranging from days to months47. PLGA
nanoparticles can be scaled for industrial manufacturing and stored for extended
periods48. Encapsulating unstable small molecules or readily degradable proteins
and oligonucleotides in core polymeric matrix will protect them from physiologic
factors that would normally facilitate its clearance. Certain compounds are readily
inactivated via hepatic metabolism or circulating proteases and endonucleases.
Additionally, the glomerular filtration unit in the kidneys rapidly clears compounds
smaller than 10 nm. Although nanoparticles avoid renal clearance, they tend to
accumulate in the mononuclear phagocyte system (MPS). Surface conjugation
with polyethylene glycol (PEG) improves particle circulation by reducing uptake
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into the MPS49. In turn, delivery via nanoparticles will extend drug half-life,
allowing for better control of circulating drug concentrations.

Figure 3: Distribution coefficient of common anti-neoplastic agents.
Table 3: Lipophilicity of common anti-neoplastic agents.
CLASS

SUBCLASS

DRUG

ALKYLATING

Aziridines
Ethylenimine

Mytomycin
Thiotepa

-0.49
0.52

Methylhydrazine
Methylmelamine
Nitrogen Mustards

Procarbazine
Altretamine
Busulfan
Chlorambucil
Cyclophosphamide
Ifosfamide
Mechlorethamine
Melphalan
Carmustine
Lomustine
Carboplatin
Cisplatin
Oxaliplatin
Dacarbazine
Temozolomide
Methotrexate

0.08
2.32
-0.52
0.55
0.23
0.23
0.87
-0.71
1.3
2.76
-1.09
-3.58
0.52
-0.29
-1.32
-4.9

Nitrosureas
Platinum

Tetrazines
ANTIMETABOLITES

Anti-folates

LOG(D)
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Purine analogues

Pyrimidine analogues

ANTI-MICROTUBULES

Epothilones
Taxanes
Vinca alkaloids

CYTOTOXIC ANTIBIOTICS

Anthracyclines

HORMONE THERAPY

Cephalotaxine
Aromatase inhibitors

Selective estrogen
receptor modulators
Anti-androgen
TARGETED THERAPY

G protein receptor
inhibitors
Histone Deacetylase
inhibitors
mTOR inhibitor
Proteasome inhibitor

Pralatrexate
Pemetrexed
Azathioprine
Cladribine
Fludarabine
Mercaptopurine
Thioguanine
Azacitidine
Capecitabine
Cytarabine
Decitabine
Gemcitabine
Floxuridine
Fluorouracil
Ixabepilone
Docetaxel
Paclitaxel
Vinblastine
Vincristine
Vinorelbine
Bleomycin
Dactinomycin
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Omacetaxine
Aminoglutethimide
Anastrozole
Exemestane
Letrozole
Testolactone
Tamoxifen

-4.35
-4.76
0.63
0.02
-0.4
-0.63
-1.12
-1.99
-0.67
-1.94
-1.93
-0.47
-0.4
-5.59
1.77
6.55
7.38
3.69
2.27
4.86
-2.13
-4.04
1.23
1.12
1.12
1.47
2.66
1.41
0.97
3.11
1.91
2.52
6.58

Toremifene
Bicalutamide
Enzalutamide
Vismodegib

6.51
4.94
2.13
2.98

Vorinostat

0.86

Everolimus
Temsirolimus
Bortezomib
Carfilzomib

3.35
2.96
2.45
6.71
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Retinoids

Serine/Threonine
kinase inhibitors
Tyrosine kinase
inhibitors

TOPOISOMERASE
INHIBITORS

Topoisomerase I
inhibitors

Topoisomerase II
inhibitors

Alitretinoin
Bexarotene
Tretinoin
Vemurafenib

4.19
5.63
4.19
3.19

Axitinib

4.15

Bosutinib
Cabozantinib
Dasatinib
Erlotinib
Gefitinib
Imatinib
Lapatinib
Nilotinib
Pazopanib
Ponatinib
Regorafenib
Sorafenib
Sunitinib
Vandetanib
Camptothecin

4.93
4.82
1.84
2.38
3.97
2.08
5.1
5.14
1.96
3.39
5.26
5.16
1.33
4.01
1.60

Irinotecan
Topotecan
Etoposide

2.71
0.45
0.30

Teniposide

1.71
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Figure 4: Nanoparticle pharmacokinetics.
1.4.3 Passive and active targeting.
Nanoparticle systems also have unique properties that allow for both
passive and active targeting of tumors. Due to up regulation of proangiogenic
signaling, most solid tumors are hypervascular. However, the new vessels have
abnormal architecture and are highly permeable. The tumor mass also has poor
lymphatic drainage, allowing for accumulation of macromolecules greater than
approximately 40 kDa within its microenvironment. Nanoparticles utilize this
phenomenon, or the enhanced permeability and retention (EPR) effect, to target
solid tumors. The ideal size range to benefit from the EPR effect is between 10
nm to 200 nm. Particles that are too small will be renally cleared, preventing
accumulation into the tumor site, and particles that are too large will not
adequately penetrate the tumor vasculature and interstitial space50,51.
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Particle surface modifications can be incorporated to improve cell targeting
and internalization while bypassing certain forms of multidrug resistance52.
Nanoparticles coupled with surface ligands or antibodies can localize to tissue
expressing the associated receptors or antigens. Certain ligand receptor
interactions will facilitate receptor-mediated endocytosis, which can further
enhance payload delivery. Surface ligand or antibody coupling can achieve
densities high enough to interact efficiently with target sites, and these
techniques lend themselves well to cancer therapies. Multiple tumors up regulate
growth factor receptors, like ErbB2 in certain breast cancers, which can be
targeted with anti-ErbB2 surface antibodies53. Various cancer lines up regulate
surface antigens, including fetoprotein, human carcinoembryonic antigen, and
human chorionic gonadotropin antigen, which provides multiple targets for
antibody mediated targeting37. Additionally, there are a wide array of cell
penetrating peptides (CPPs) or targeting peptides that can facilitate interactions
with tumor cells or tumor endothelium. Established conjugation chemistries
provide facile mechanisms for surface modifying polymer nanoparticles with
targeting peptides. Zhou et al54 optimized multiple CPPs for improved particle
endocytosis, and Teesalu et al55,56 used the novel internalizing RGD (iRGD)
peptide to target nanoparticles to the tumor endothelium. The RGD peptide
sequence recognizes the αvβ3/αvβ5 integrins up regulated on tumor endothelial
cells. The iRGD peptide is a cyclic tumor homing structure which contains both
the RGD sequence and a CendK/R element. The iRGD structure is readily
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cleaved by proteases, allowing for exposure of the CendK/R element and
subsequent tissue penetration through binding of neuropilin-1(Figure 5)57.

Figure 5: Mechanism for iRGD binding and penetration.
In addition to ligand coupled targeting, nanoparticles can be delivered
locally via intravenous catheters, inhalation, transdermal patches, or intravitreal
administration52. Local delivery of chemotherapeutic agents can minimize several
of the harmful side effects associated with common cancer therapies. New
polymer delivery vehicles allow for targeted and combination cancer therapies,
which can ultimately decrease the development of drug resistance while
simultaneously minimizing the side effect profile.
1.4.4 Nanoparticle gene therapy.
Gene therapy is the cellular delivery of nucleic acids in order to modulate
gene expression towards treating disease. After introduction, the therapeutic
DNA either integrates into the host genome or persists as an episomal vector.
Phenotypic modulation is achieved either through gene addition, gene correction,
or gene knockdown58. Gene addition is generally the most common approach,
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and alters cell behavior by introducing genetic material and consequent proteins
that are inherently missing in the host. Gene correction is less common, and
utilizes DNA recombination technology, like zinc finger nucleases, triplex forming
oligonucleotides, or CRISPR-Cas technology, to alter or correct genomic
sequences59-62. Finally, gene knockdown through RNAi has received significant
enthusiasm. Due to the complex nature of cancer pathogenesis and multitude of
signaling pathways involved in disease progression, isolating druggable
molecular targets can become increasingly difficult. Often, tumor cells have
altered transcription factor activity, which are difficult to target through small
molecule drugs. Therefore, gene therapy can provide an alternative strategy for
designing effective and specific therapies against cancer.
The FDA approved its first clinical trial in gene therapy in 1990. Michael
Blease conducted an ex vivo gene therapy trial on two children with adenosine
deaminase deficiency, a form of severe combined immunodeficiency (SCID), with
limited efficacy63. Subsequent trials in treating SCID through ex vivo gene
delivery, however, have demonstrated better long term results64,65. In 1998, A
team in Scandinavia demonstrated the first successful gene transfer from in vivo
gene delivery into the brain66. Currently, there have been greater than 1,800
approved clinical trials worldwide67. More than 60 percent of current trials are
designed to treat cancer, and viral vectors continue to be the most popular
approach68. China was the first country to approve a commercial gene
therapeutic, which is currently being used to treat head and neck cancer69, and
there are multiple therapies nearing the final stages of clinical testing
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worldwide70. Of interest, the CTL019 trial, at the University of Pennsylvania, has
shown promising results using chimeric antigen receptor therapy for treating Bcell neoplasms71-73. The patient’s T-cells are modified ex vivo using a lentiviral
vector to express chimeric surface antibodies against CD19, which is expressed
on B-cells. Twelve of 14 pediatric patients with acute lymphoblastic leukemia
have responded to therapy, and eight experienced complete remission. Twelve
of 24 adult patients with chronic lymphocytic leukemia have responded to
therapy, and five of those responders have attained complete remission74.
There has been significant progress in the field, despite earlier setbacks,
including the death of 18 year old Jesse Gelsinger in 199975, and the
development of T cell leukemia in multiple patients receiving gene therapies for
SCID76,77. Severe side effects like mortality and carcinogenesis were intimately
related to the viral delivery vector. The dangers of viral gene therapy are due to
the associated acute immune response, immunogenicity, and oncogenesis. Even
the recently successful CTL019 therapy, has significant toxicities including the
development of cytokine release syndrome which can progress into macrophage
activation syndrome71. Safety concerns are the underlying basis for research into
synthetic vectors for gene delivery. Further, viruses have limited payload capacity
and are difficult for large-scale production. Non-viral vectors are advantageous
due to their safety profile, low cost, large scale manufacturing potential, stability,
and capacity for a larger nucleic acid payload78,79. The main limitation of non-viral
vectors is their lower transfection efficiency. Table 4 lists the array of different
vectors for gene therapy, and their associated transfection efficiency and toxicity.
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PLGA nanoparticles can deliver nucleic acids with minimal cytotoxicity, but they
have relatively low transfection efficiency. Incorporation of counter ions, like
spermidine, and surface functionalization with cell targeting or cell penetrating
peptides have improved DNA loading and particle transfection54,80. However,
their transfection efficiency remains far less than the polycationic nanoparticle
formulations and viruses.
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Table 4: Methods of gene delivery56,58,78,79,81,82.
CATEGORY

GENE DELIVERY
TRANSFECTION TOXICITY
SYSTEM
EFFICACY
INORGANIC
Calcium Phosphate
II
I/II
Gold
Magnetic
Silica
Quantum dots
CATIONIC LIPIDS
Emulsions
II/III
II/III
Liposomes
Lipid nanoparticles
CATIONIC POLYMERS
PAMAM
II/III
II/III
PbAE
PEI
Terpolymers
CATIONIC PEPTIDE
GALA,KALA
II/III
II/III
Poly-L-lysine
Protamine
Self-assembling
peptides
POLYMER
Chitosan
II
I/II
Copolymer micelles
PLGA, PLA
Polymethacrylates
HYBRID
Lipid-polycationic
I/II
I/II
polymer
PLGA-polycationic
polymer
PLGA-lipid
PHYSICAL
Needle
II/III
II/III
Ballistic DNA
injection
Electroporation
Sonoporation
Photoporation
Magnetofection
Hydroporation
VIRAL
Retroviral
III
III
Adenoviral
Adeno-associated
I-low, II-medium, III-high, GALA- glutamic acid-alanine-leucine-alanine, KALA- lysine-alanineleucine-alanine, PAMAM-polyamidoamine, PbAE- poly(beta-amino ester), PEI-Polyethyleneimine,
PLA-polylactic acid, PLGA- poly(lactic-co-glycolic acid).

Cationic liposomes are currently the gold standard for nanoparticle
transfection. The first gene therapy trial using cationic liposomes occurred in
1992, and approximately 13 percent of all gene therapy trials worldwide are using
liposomal nanoparticles. Toxicity, however, can also be a major concern of
liposomes. Additionally, liposomes are heterogeneous and relatively unstable,
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causing significant obstacles for large-scale pharmaceutical production83.
Liposomes are readily inactivated in the serum, which can lower the high
transfection levels commonly seen in vitro84. Serum instability, clearance, and
cytotoxicity are common obstacles facing many non-viral gene delivery vectors.
Polycationic polymers, like polyethyleneimine (PEI), have high in vitro
transfection potential but can also be considerably cytotoxic. PEI induces
channel formation on the mitochondrial membrane and subsequent caspase
activation and apoptosis85. Other polycations, like poly-L-lysine (PLL) and
chitosan, are less toxic but provide lower transfection. Further, PLL can stimulate
an immune response due to the introduction of foreign amino acid sequences,
and chitosan, at high doses can result in hypolipidemia in vivo83.
In addition to cytotoxicity, multiple barriers can obstruct effective particle
transfection(Figure 7)58,81,82. Gene loaded particles need to protect their payload
from nucleolytic enzymes while in circulation, and ultimately penetrate into the
target tissue at adequate concentrations. Polymers like PLGA can encapsulate
nucleic acids, protecting them from endonucleases. Similarly, condensing the
negative phosphate bonds of nucleic acid chains with cationic polymers into
polyplexes can also protect the oligonucleotides from degradation during
circulation. As discussed earlier, nanocarriers can utilize the EPR effect or
specific integrin binding in order to target the tumor endothelium and promote
vessel extravasation. By conjugating peptides, like iRGD, particles can
preferentially accumulate in specific tumor locations.
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After bypassing the vascular endothelium, the particle will then need to
traverse the interstitial space towards the target cell. Nanoparticle uptake
depends on a variety of biophysiochemical characteristics of both the particle and
cell surface. The cell surface is highly heterogeneous, both spatially and
temporally, due to a variety of membrane structures, molecular interactions, and
transport processes. Therefore, uptake will depend on both chance interaction
and specific particle cell surface dynamics86. Surface charge and particle size are
intimately associated with uptake efficiency. The numerous cell surface proteins
provide an overall negative charge on the plasma membrane, which readily
interacts with the positive charge on certain nanocarriers. Optimal particle
diameter ranges from 50-120 nm, and smaller particles experience faster
uptake87. Additional studies report clathrin or caveolin mediated endocytosis are
capable of internalizing particles with diameters upwards to 500 nm, yet
internalization efficiency decreases with increased size88. Due to particle charge
and size, uptake via membrane channels or transmembrane diffusion is unlikely.
Therefore, energy dependent endocytosis is a primary route for cellular entry and
can occur through multiple mechanisms. Figure 6 illustrates the five major
endocytic pathways. Each route has its associated molecular players,
compartment size, and intracellular fate89-91. There are multiple destinations for
the early endosome, and the majority will render the genetic material ineffective.
Figure 7 depicts different destinations for the endosomal cargo, and early escape
is necessary for subsequent gene activity. Endosomal acidification and payload
degradation through the lysosomal pathway (L) is a common barrier for
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transfection. Sequestration within vesicles (V) can also occur, as can
externalization through trancytosis or endosomal recycling, all of which will
render the genetic payload ineffective.

Figure 6: Pathways for endocytosis.
AP – antennapedia, CDC42 - cell division cycle 42, CLIC-D - dynamin-dependent clathrinindependent carriers, CLIC-DI - dynamin- and clathrin-independent carriers, ER – endoplasmic
reticulum, RGD - arginine-glycine-aspartic acid, TAT – transactivator of transcription, TGN –
trans-Golgi network, TK – Tyrosine kinases
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Figure 7: Barriers to gene therapy.
CTL – cytotoxic T lymphocyte, L – lysosome, V – vesicle. R – endosomal recycling, T –
transcytosis.

Additionally, ligand surface modifications not only assist particle targeting,
but may also facilitate uptake. CPPs are classes of short 30-35 amino acid
peptides, rich in arginine and lysine, that promote cargo uptake via multiple
mechanisms. The prototypic CPP are the HIV transactivator of transcription
(TAT) peptide and antennapedia (AP) peptide isolated from Drosophila

29
antennae92. Currently, there are multiple studies evaluating these peptides, and
their influence on cargo endocytosis. The specific mechanism for endocytosis
varies, and several studies have suggested multiple routes of entry for individual
CPPs93-95. Of interest, Zhou et al. evaluated histidine modifications of several
CPPs, and found that flanking AP with five histidine residues (mAP) significantly
increased nanoparticle transfection efficiencies54. Additionally, particle surface
modifications with anti-receptor antibodies, or surface conjugation with folate and
transferrin can increase cargo uptake96-98. Figure 6 summarizes targeting
strategies for specific endocytic pathways. Strategies to improve endosomal
escape include utilizing fusogenic peptides or the proton sponge effect. Certain
viral peptides are known to promote endosomal disruption in a pH dependent
manner, and similar peptides have been synthesized to improve gene
transfection when incorporated with DNA polyplexes99. Due to immunotoxicity of
viral proteins, synthetic peptides have been designed to enhance endosomal
disruption as well. These polymers are converted from hydrophilic to hydrophobic
structures upon protonation in the endosome, which consequently allows for
vesicle membrane lysis100. Cationic polyplexes, like PEI or polyamidoamine
(PAMAM) dendrimers, can also promote endosomal escape through the proton
sponge mechanism101. During endosomal acidification, the protons pumped into
the lumen via the vacuolar-ATPase are buffered by the polyamine dendrimers.
The impairment in acidification results in increase proton influx, which passively
recruits chloride ions in order to maintain charge balance. The greater
accumulation of osmotic agents results in endosomal swelling and consequent
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lysis. Additionally, co-delivery of chloroquine analogues has been shown to
improve gene transfection through unclear mechanisms. There is support that
chloroquine can potentially act as pH buffering agents as well, displace cationic
complexes from nucleic acids, or alter biophysical properties of the released
genetic material102.
If the nanocarrier does escape the endosome, depending on the genetic
payload, the next challenge will be nuclear targeting. Plasmid delivery will require
translocation into the nucleus to attain transcription, whereas siRNA or miRNA
activity resides in the cytoplasm. Additionally, cytosolic nucleases will eventually
degrade cytosolic DNA or RNA. Polyplexes can potentially protect against
cytosolic nucleases and travel along microtubules towards the nucleus via
nonspecific charge interactions. Additionally, random redistribution during mitosis
can result in gene uptake within the nucleus. Nuclear localization signals (NLS),
which are naturally occurring cationic peptides, are used to deliver proteins to the
nucleus. Polyplexes may act similarly to these NLS due to their inherent positive
charge. NLS can also be conjugated to plasmids to imporove nuclear targeting
and transfection103. Co-delivery of trans-cyclohexane-1,2-diol (TCHD) has been
shown to improve gene transfection through non-selective gating of the nuclear
pore104. Within the nucleus, vector genome persistence may be an issue if the
exogenous material does not integrate with the hose genome. The episomal
DNA can persist in quiescent tissue; however, gene expression will become
increasingly transient in rapidly dividing cells. Repeat dosing may then be
required to sustain therapeutic transfection levels. Vector integration into the host
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genome can lead to greater persistence at the risk of gene disruption via
insertional mutagenesis. Additionally, epigenetic alterations may disrupt gene
expression regardless of genome integration. Persistence and sustained gene
expression are vital for diseases requiring permanent gene expression. For
acquired diseases like cancer, transient transfection may be adequate to achieve
a therapeutic effect. Alternatively, minicircle DNA vectors lacking bacterial DNA
has been shown to be expressed at high levels in vivo for extended periods, yet
obstacles in their mass production limit their utilization105.
The host immune response is a significant barrier to efficient gene therapy
as well. Particle components, extranuclear nucleic acids, and transgene products
can activate an immune response. It is difficult to predict human immune
responses since most animal models fail to replicate the human immune systems
accurately. Not only is the immune response hard to extrapolate into humans, but
transfection efficiencies measured in animals do not always correlate into
humans58. Generally, the immune response elicited by viral vectors is far more
severe than that of nanoparticles, as most particles are only as immunotoxic as
their cargo. Although, foreign DNA payloads can also illicit an interferon response
which can potentially lead to immunotoxicity or decreased transfection
efficiencies106. The inflammatory response may be due to the presence of
unmethylated CpG dinucleotides present on plasmid DNA. Mutating the
immunostimulatory CpG motifs or co-delivering immunosuppressants can
decrease the inflammatory response and elevate transgene expression107.
Additionally, higher surface charges present on liposomes have induced
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secretion of cytokines including tumor necrosis factor (TNF), interleukin 12,
nuclear factor κβ (NFκβ), and interferon γ. However, these immunostimulatory
effects may be beneficial in cancer therapies108-110.
The MPS plays a major role in nanoparticle clearance. Nanoparticles
readily adsorb plasma proteins upon introduction to systemic circulation, and are
consequently opsonized and phagocytized by the MPS. Due to hepatic and
splenic filtration, particles tend to accumulate in those organs111. Smaller
particles and a neutral surface charge result in lower levels of opsonization and
phagocytosis. Surface modifications can reduce protein adsorption and
entrapment within the MPS. For instance, PEG not only decreases protein
adsorption and phagocytis into the MPS as discussed earlier, but it can also
decrease platelet or erythrocyte interactions112. Unfortunately, the shielding
effects of particle PEGylation is transient and can hinder target particle cell
interactions as well. Poloxamer and poloxamine have also been used to reduce
recognition from immune cells, decrease uptake within the MPS, and prolong
circulation time113. Additionally, surface functionalization with self-peptides, like
CD47, can delay macrophage mediated clearance114. Nanoparticle design
becomes critical in order to address the multiple barriers involved in gene
transfection, and Table 5 summarizes the common strategies utilized in particle
engineering.
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Table 5: Strategies for addressing gene delivery barriers via nanoparticles.
BARRIER

STRATEGY

1. STABILITY IN TRANSPORT AND TARGETING.

Local delivery
Polymer encapsulation
Polyplexes
Surface modifications (see text)

2. UPTAKE.

Fabricate at optimal particle size
Surface modifications (Figure 6 and
text)

3. ENDOSOMAL ESCAPE.

Chloroquine analogues
pH sensitive fusogenic or synthetic
peptides
‘Proton sponge’ polymers

4. TRANSPORT INTO NUCLEUS.

Nuclear pore gating with TCHD
Nuclear targeting via NLS

5. PERSISTENCE AND TRANSCRIPTIONAL
ACTIVITY.

Insertional vectors
Minicircle DNA vectors
Repeat dosing

6. IMMUNE RESPONSE.

Co-deliver immunosupressants
Fabricate at optimal particle size
Minicircle DNA vectors
Mutate CpG motifs on plasmid DNA
Neutral surface charge
Surface modifications (see text)

NLS – Nuclear localization signal, TCHD - trans-cyclohexane-1,2-diol.
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1.5

Apoptosis and cancer.

1.5.1 Apoptotic signaling and evading cell death.
Apoptosis is a highly regulated mode of cell death, where internal
signaling cascades promote degradation of nuclear DNA and cellular proteins.
During the process, the plasma membrane remains intact, and eventually
neighboring cells or macrophages engulf the cellular remnant. Activation of
cysteine proteases, or caspases, is a primary driver of apoptosis. Two upstream
circuits, divided into the extrinsic and intrinsic pathways, regulate this signaling
cascade. The extrinsic pathway is initiated by extracellular death inducing signals
that bind to death receptors (DRs) on the cell surface. The majority of these
receptors are members of the TNF receptor family, and they bind to specific
ligands including the Fas ligand (FasL), TNFα receptor, and tumor necrosis
factor-related apoptosis inducing ligand (TRAIL). DR binding activates caspase8, which subsequently activates caspase-3 and -7, resulting in the execution of
apoptosis. Caspase-8 can directly regulate the mitochondrial pathway as well by
activating proapoptotic proteins, Bax and Bak, which form channels in the outer
mitochondrial membrane, and in turn releases cytochrome c. In the cytoplasm,
cytochrome c engages downstream caspases towards inducing apoptosis. Antiapoptotic proteins maintain cell viability by binding and inhibiting Bax and Bak
and caspase activation. Cell survival mediators and growth receptor signaling
provide anti-apoptotic signals through the Bcl-2 family or inhibitor of apoptosis
proteins (IAPs). Cellular stresses including loss of growth factors, oxidation,
endoplasmic reticulum stress due to misfolded proteins, and DNA damage can
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inhibit anti-apoptotic proteins and activate pro-apoptotic Bcl family proteins. This
subclass of Bcl proteins is commonly known as BH3-only proteins, and they
activate Bax and Bak towards releasing cytochrome c. BH3-only proteins can
directly inhibit Bcl-2 as well. Crosstalk between the extrinsic and intrinsic
pathways tightly regulates the caspase mediated apoptotic pathway(Figure 8)115.
Chemotherapies and radiotherapies can induce apoptosis in susceptible
cancer cells. Many antineoplastic agents increase DR expression via a TP53
mechanism or DR ligand synthesis116,117. However, tumor cells have developed
numerous mechanisms to reduce or even avoid apoptosis. The most prominent
is the loss of tumor suppressor TP53, which senses DNA damage and promotes
apoptosis through directly activating caspase-8, Bax, and Bak. Loss of TP53 will
desensitize cells to ionizing radiation or DNA damaging chemotherapeutics.
Additionally, tumors can modulate any part of the circuitry, through either upregulating growth receptor signaling or Bcl-2 expression, down-regulating BH3only or IAP protein expression, or inactivating extrinsic DR signaling7.
Augmentation of the intrinsic and extrinsic apoptotic pathways is intimately
associated with cancer development, and in turn linked to the development of
drug resistance118. Apoptotic signaling is a promising target for anticancer
therapies, since there are multiple signaling networks to target, and direct
interplay between the different pathways.
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Figure 8: Apoptosis signaling cascade.
CPT – camptothecin.

1.6

Combination therapies and synergism.

1.6.1 Nanoparticle combination therapies.
Combination therapies with nanoparticles are promising due to their
manufacturing benefits, and ideal pharmacokinetics and biophysiochemical
characteristics119. Combination drug analyses have often been difficult to
translate from in vitro to in vivo experiments. Delivering multiple agents in vivo is
complicated due to their independent pharmokinetics, biodistribution, and
clearance. Nanoparticle delivery systems will consolidate these properties into
one vehicle and ultimately ensure that the targeted tumor cells receive both
agents at a ratiometric dose. Therefore, the optimal drug ratio can be tuned in
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vitro, and subsequently translated to the clinic effectively. Combining multiple
agents into one carrier can also streamline manufacturing and infusion
processes, overcome batch to batch variability, and lower costs. The patient will
also receive smaller doses of the nanocarriers, which can potentially lower
toxicity associated with the delivery vector. There have been several reports of
co-delivering multiple anti-cancer agents using nanocarriers, and some are
reaching clinical trials120-124. Only a few, however, are capable of co-delivering
both small molecule chemotherapeutics and genetic material. As these carriers
show considerable promise, improvements are still necessary in improving
transfection potential, while maintaining ideal particle size, surface charge,
loading, targeting, and biocompatibility. Additionally, evaluation of synergistic
interactions is rare, especially when using nanoparticle vectors for co-delivery.
Several of the reported nanocarriers were only able to show improved anticancer effects at high doses.
1.6.2 Chou-Talalay analysis of synergism.
Designing therapies with synergistic agents will allow for reduced drug
dosing and toxicity. Two agents act synergistically when their combined effect is
greater than the sum of their individual effects. Analysis of synergism is complex
and there are numerous methods for determining true synergism. Several of
these methods contradict the other. Although commonly presented, the
arithmetic sum of individual effects does not necessarily provide a cutoff for
synergism, since you cannot have effect levels greater than one. Potency as well
as efficacy is important in determining synergy, and therefore a dose response
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curve is necessary for accurate analysis. Chou and Talalay derived the
combination index (CI) and median effect equation (MEE) in 1984, and have
since established a precedent for analyzing synergism125,126. The MEE is derived
from the mass action law, and describes the behavior of many biological
systems. In fact, the Michaelis-Menten, Hill, Henderson-Hasselbalch, and
Scathcard equations can be derived from the MEE. Therefore, the mechanisms
of action and conventional kinetic constants for the individual agents are not
necessary to evaluate synergism via this method. The linearized MEE uses the
dose response data to determine Dm, the median effective dose, and m, the Hilltype coefficient(Equation 2). The coefficient for the linear regression is an
indicator for the applicability of the Chou-Talalay analysis. At each effect level,
the corresponding doses, Dalone,1, Dalone,2, Dcomb,1, and Dcomb,2, can be tabulated to
determine a CI value, using Equation 3, which can consequently be evaluated
according to Table 6. The doses for individual agents during the combined dose
response analysis are determined using the known ratio between the two
components. Finally, a calculated dose-reduction index (DRI) can provide the
fold change in drug dosing required to achieve a similar effect(Equation 4). A
computer program, CompuSyn, is available to assist with the Chou-Talalay
analysis127. Chaowanachan et al. evaluated drug synergism between tenofovir
and nanoparticle antiretrovirals using the Chou-Talalay analysis, however, to my
knowledge, there have not been any previous analyses of synergism for
nanocarrier combination therapies128.
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Equation 1: MEE
𝑓𝑓𝑎𝑎
𝐷𝐷 𝑚𝑚
=� �
𝑓𝑓𝑢𝑢
𝐷𝐷𝑚𝑚

D – dose, Dm – median effect dose, fa – fraction affected, fu – fraction unaffected, m – Hill-type
coefficient.

Equation 2: Linearization of the MEE
𝑓𝑓𝑎𝑎
log � � = 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚(𝐷𝐷) − 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚(𝐷𝐷𝑚𝑚 )
𝑓𝑓𝑢𝑢
𝑓𝑓𝑎𝑎 + 𝑓𝑓𝑢𝑢 = 1

Equation 3: CI

log�𝑓𝑓𝑢𝑢 −1 − 1� = 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚(𝐷𝐷) − 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚(𝐷𝐷𝑚𝑚 )
𝐶𝐶𝐶𝐶 =

𝐷𝐷𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,1 𝐷𝐷𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,2
𝐷𝐷𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,1 𝐷𝐷𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,2
+
+∝
𝐷𝐷𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎,1 𝐷𝐷𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎,2
𝐷𝐷𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎,1 𝐷𝐷𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎,2

CI – combination index, Dalone,1 – dose of drug 1, Dalone,2 – dose of drug 2, Dcomb,1 – combination
dose of drug 1, Dcomb,2 – combination dose of drug 2. For mutually exclusive drugs, ∝ = 0, and for
mutually nonexclusive drugs, ∝ = 1.
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Table 6: Evaluation of Combination Index values125,126.
CI RANGE

EVALUATION

<0.10

Very strong synergism

0.10-0.30

Strong synergism

0.30-0.70

Synergism

0.70-0.85

Moderate synergism

0.85-0.90

Slight synergism

0.90-1.10

Nearly additive

1.10-1.20

Slight antagonism

1.20-1.45

Moderate antagonism

1.45-3.30

Antagonism

3.30-10.0

Strong antagonism

>10.0

Very strong antagonism

Equation 4: Dose-Reduction Index
𝐷𝐷𝐷𝐷𝐷𝐷1 = 𝐷𝐷𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎,1 /𝐷𝐷𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,1

DRI – Dose-reduction index, Dalone,1 – dose of drug 1, Dcomb,1 – combination dose of drug 1.

1.7

Candidate agents.
Apoptosis is often deregulated in cancer cells. As most FDA approved

modes of cancer therapy result in modulation in apoptosis, alterations in cell
death signaling is common in many tumor subtypes and will ultimately result in
resistance to most treatment protocols. New strategies to improve cancer
therapies can focus on improving apoptosis through combination therapies
targeting both the extrinsic and intrinsic pathways. Rational nanomedicine design
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for combination cancer therapies should utilize the attractive biophysicochemical
properties of nanoparticles, for providing multi-modal cancer therapies.
1.7.1 Camptothecin.
Numerous small molecule chemotherapeutic agents are promising
candidates for delivery via polymer nanoparticles. Camptothecin (CPT) is a
hydrophobic, topoisomerase I (topo-1) inhibitor, and lends itself well to polymer
nanoparticle delivery. It is an alkaloid extract from the Chinese tree,
Camptotheca acuminate, and was first identified in 1966 through a natural
product screen for antitumor agents. Due to its hydrophobic nature, CPT readily
penetrates eukaryotic cell membranes and targets topo-1 within minutes. CPT
stabilizes topo-1 after binding to DNA, and prevents religation129. As the
replication fork collides with the cleaved strand, it induces a double stranded
break resulting in cell cycle arrest and apoptosis. Downstream signaling after
DNA breaks has also been shown to increase expression of NFκβ and surface
DRs130. Mutations in DNA repair pathways can further sensitize tumor cells to
CPT, however, deficiencies in the cell cycle checkpoint process can have the
opposite effect. CPT has a low affinity to topo-1, which necessitates prolonged
infusions. Initial clinical trials evaluating CPT were halted due to severe toxicities
including myelosuppression and hemorrhagic cystitis. The major limiting factors
were the associated toxicity, stability, and low solubility in water. CPT contains a
lactone component that is required for binding topo-1. However, the lactone is
readily hydrolyzed in aqueous solutions to the inactive carboxylate form and
readily binds serum albumin(Figure 9). Decreasing pH can promote reformation
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of the active form of CPT, which may provide a targeting benefit given that tumor
microenvironments are relatively acidic131. Water-soluble analogues, such as
topotecan and irinotecan, are currently FDA approved and are used as both first
line and refractory therapies130. PLGA particles can readily encapsulate CPT due
to its hydrophobic qualities, provide protection from lactone hydrolysis and
albumin binding while in circulation132. The molecule also has a strong
fluorescence (370 nm excitation, 428 nm emission) which can allow for facile
loading and release measurements133. CPT is a promising candidate drug for
combination therapies via polymer nanoparticles due to its chemical properties
and unique mechanism of action.

Figure 9: Reversible hydrolysis of camptothecin.
1.7.2 TNF-related apoptosis inducing ligand (TRAIL)
Scientists at Genentech and Immunex identified the new TNF-superfamily
member peptide, TRAIL, through analyzing the human genome database for
homologous sequences to TNF134. TRAIL is a strong inducer of apoptosis via the
extrinsic pathway, and it preferentially targets cancer cells independently of TP53
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status135. Through binding DRs, specifically DR4 and TP53 regulated DR5,
TRAIL activates the caspase mediated apoptosis cascade(Figure 8). Its
physiologic role is not completely delineated, yet it has been implicated in
antitumor surveillance. Natural killer cells (NK cells), monocytes, and T cells all
express TRAIL to induce apoptosis in cancer cells. T cells can both display
TRAIL and secrete soluble forms of the ligand136. Recombinant soluble TRAIL
induces apoptosis in a variety of solid and liquid tumors, with minimal associated
systemic toxicities137-144. Normal tissues exhibit a tightly regulated mechanism to
control against TRAIL induced cell death involving decoy receptors. Certain
recombinant forms of TRAIL can promote apoptosis in hepatocytes, astrocytes,
and keratinocytes, which may be related to high order multimerization of DRs
secondary to peptide aggregation. Alternatively, soluble, zinc-bound, nonaggregating, recombinant TRAIL induces less off target apoptosis, however, it is
less effective in killing tumor cells136,145. Therapeutically, alternate DR targeting
using TNAα has resulted in septic shock responses due to activation of NFκβ,
and FasL resulted in hepatic failure136. TRAIL is a safer alternative since it rarely
targets normal cells, and it minimally activates NFκβ signaling. Several cancer
cell lines highly express DR4 and DR5, and multiple lines up-regulate DR
expression upon exposure cytotoxic agents and ionizing radiation135-137. TRAIL’s
safety profile, and tumor specific, TP53 independent, activity are promising
qualities. The biggest hurdle for the clinical use of recombinant TRAIL peptide is
its serum instability and rapid clearance. Even the larger, multimeric formulations
are rapidly cleared by the kidneys. In vivo studies in mice report TRAIL activity
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for only 3-5 minutes, and current therapies in animal models require prolonged
infusions at high doses shortly after tumor implantation145,146.
Despite TRAIL’s broad range of anti-tumor activity, newer studies are
isolating several resistant cell lines, which may also benefit from combination
therapies. Multiple chemotherapeutic agents, including doxorubicin and CPT, act
synergistically with recombinant TRAIL therapy resulting in significant tumor
regression or complete remission. Of interest, TRAIL gene transfection has been
shown to kill resistant prostate cancer cell lines without the need for
doxorubicin147. A phase I trial using an adenoviral vector for TRAIL transfection
has been completed for treating prostate cancer148. TRAIL transgene expression
has been implicated with cell death as well as bystander cell toxicity in tumors,
suggesting that 100 percent cell transfection is not necessary for therapeutic
efficacy149. Targeted cellular transfection can potentially allow for sustained
TRAIL expression with minimal interference from systemic clearance.
Transfection may provide an alternative strategy for TRAIL therapies that would
overcome the need for long, high dose, recombinant protein infusions.
1.7.3 Combination therapies with camptothecin and TNF-related apoptosis
inducing ligand.
CPT analogues and TRAIL produce significantly enhanced apoptotic activity
when administered in combination150. For instance, irinotecan (CPT-11), was
shown to cooperate with TRAIL to produce TP53 independent apoptosis of colon
cancer cells. Hepatic metastases from both TP53 proficient and deficient tumor
cells were eliminated with combined TRAIL and CPT-11 therapy. Ravi et al.
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suggest that a TP53 independent mechanism may assist in the cross-talk
between the two apoptosis inducing agents151. Several tumor cell lines have
demonstrated favorable responses to combined TRAIL and CPT analogue
therapies, including colon cancer, prostate cancer, brain cancer, breast cancer,
and lung cancer152-155. Timing of agent delivery was an important factor in
therapy, as the majority of these studies found that pretreatment with
chemotherapeutic drugs or radiation enhanced subsequent recombinant TRAIL
activity. In turn, nanoparticle delivery systems may provide an ideal system for
providing combination CPT and TRAIL gene therapies.

2 Statement of Purpose and Hypothesis
Our understanding of tumor biology has improved significantly, yet cancer
remains a highly prevalent and lethal disease. Small molecules,
immunotherapies, and gene therapies are providing numerous therapeutic
options and the potential for personalized medicine. However, there are still
significant obstacles in treating cancer, primarily due to the development of tumor
resistance and severe side effects. Combination therapies are becoming
increasingly common as front line therapies, yet side effects often limit treatment
dosing, duration, and ultimately efficacy. Targeted therapies, utilizing multiple
synergistic agents tailored for individual patients, can potentially address these
obstacles. Polymer nanoparticle technology provides an attractive vector for
delivering multi-modal therapies against cancer in a targeted manner. We
hypothesize that by utilizing multi-layered polymer nanoparticles (MLNPs),
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we can rationally design a multi-functional delivery vector for combination
gene and small molecule therapy towards synergistically inhibiting tumor
growth. There have been previous studies examining the use of nanoparticles
for multi-modal therapies. However, improvement in gene transfection is
necessary, while maintaining ideal particle biophysicochemical properties.
Combination therapies via nanovectors will also require thorough analysis of
synergism in order to reduce therapeutic dosage. Therefore, our investigations
will address the following:
1. Improve PLGA particle transfection in vitro by adjusting particle
fabrication parameters, utilizing surfaces modifications, and coencapsulating transfection enhancing small molecules.
2. Examine tumor death kinetics in vitro in response to TRAIL gene
transfection and CPT exposure towards optimal delivery with MLNPs.
3. Demonstrate synergistic decrease in tumor cell growth in vitro by codelivering CPT and a plasmid encoding for the TRAIL gene (pTRAIL).
4. Demonstrate efficacy in reducing tumor growth in vivo by co-delivering
CPT and pTRAIL gene via MLNPs.

3 Methods
All of the authors were involved in developing the final design for the MLNPs.
The first author performed all of the experiments detailed in this thesis. All of the
authors were involved in the analysis and interpretation of the data.
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3.1

Materials and cell culture.
All reagents were purchased from Sigma Aldrich unless otherwise noted.

Plasmid DNA (pDNA) expressing luciferase (pGL4.13; pLuc), green fluorescent
protein (GFP; pEGFP; pGFP), and TRAIL (pEGFP-TRAIL; pTRAIL) were
purchased from Promega and Addgene respectively. Human embryonic kidney
293 (293T), human glioblastoma (U87), human colorectal adenocarcinoma
(HCT116), and human breast adenocarcinoma (MDAMB231) cell lines were
obtained from ATCC (American Type Culture Collection). All cells were grown in
same culture media (CM), which consisted of DMEM medium (Life Technologies)
supplemented with 10% fetal bovine serum (Life Technologies), 100 units/ml
penicillin, and 100 mg/ml streptomycin (Life Technologies), in a 37C incubator
containing 5% CO2. Fluorescence was determined using a UV-Vis
spectrophotometer (Cary 50 Bio UV-Vis Spectrophotometer, Varian, Palo Alto,
CA).
3.2

Nanoparticle fabrication.
Nanoparticles (NPs) were fabricated using established emulsion

evaporation techniques. PLGA (50:50 PLGA Carboxylic Acid End Group; i.v.
~0.67 dL/g; Absorbable Polymers: Pelham, AL) was dissolved in organic solvent
(ethyl acetate (EA) or dichloromethane (DCM)) at a ratio of 50 mg polymer to 1
mL organic solvent to form the oil phase (O). For drug loaded particles, CPT was
dissolved at designated concentrations (5 mg/mL to 0.0001 mg/mL) in O. The
polymer solution was then added dropwise to the outer aqueous phase (W2)
which consisted of deionized water containing 2.5% (v/v) poly-vinyl alcohol (PVA)
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at a ratio of 1 mL O to 2 mL W2. The O/W2 emulsion was sonicated on ice three
times for 10 s (Tekmar, 600 Watts 38%). When indicated, TCHD was
incorporated by adding 12.5 uL of 200 mg/mL TCHD in deionized water as the
inner aqueous phase (W1), and added dropwise to O. This W1/O emulsion was
sonicated as above, and then added to W2 at the same ratio as above. The final
O/W2 or W1/O/W2 emulsion was then diluted 25 fold into 0.3% (v/v) PVA in
water. The diluted emulsion was left stirring at 400 rpm for at least 3 h. NPs were
then centrifuged at 13,000 rpm for 15 min at 4C. All centrifugation steps were
performed using these parameters. The supernatant was then decanted and the
pellet was resuspended in 4 mL water by sonication for 10 sec in a water bath
sonicator. Particles were always resuspended using these sonication
parameters. Resuspended NPs were flash frozen in liquid nitrogen and
lyophilized for long-term storage at -20C.
3.3

Surface modification
MLNPs were fabricated by forming PLGA nanoparticles as above with an

outer aqueous phase containing PEI (3.3 mg/mL). After spinning overnight, the
particles were centrifuged and resuspended in 1 mL of pH 4.0 sodium acetate
buffer containing 25 µg/mL of pDNA. The particle suspension was loaded on a
rotisserie shaker for 15 min at room temperature (RT), and then centrifuged and
resuspended in 1 mL of 10 mg/mL PEI in pH 4.0 sodium acetate buffer. The
particle suspension was loaded on a rotisserie shaker for 15 min at RT, and then
centrifuged and resuspended in 1 mL of pH 7.4 phosphate buffered saline (PBS)
containing 1 mg/mL of a heterobifunctional PEG linker (Peirce Thermo Scientific).
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The PEG linker was functionalized with N-hydroxysuccinimide (NHS) and
maleimide (MAL). The particle suspension was loaded on a rotisserie shaker for
30 min at RT, and then centrifuged and resuspended in 1 mL of pH 7.4 PBS
containing 2 mg/mL mAP (W. M. Keck Facility at Yale University). The particle
suspension was loaded on a rotisserie shaker for 30 min at RT, and then
centrifuged and resuspended in 4 mL water. Final MLNP suspension was flash
frozen in liquid nitrogen and lyophilized for long term storage at -20C. Step by
step illustration of the conjugation steps are illustrated in Figure 10.
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Figure 10: Surface modification of MLNPs.
3.4

Cellular Transfection
For 96 well plates, the culture volume was 100 µL and for 48 well plates,

the culture volume was 250 µL. Cells were seeded at designated seeding
densities in CM without antibiotics, and transfected 24 h later. For polymer NP
transfections, the CM was removed and replaced with NPs or MLNPs
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resuspended in CM containing antibiotics at designated particle concentrations.
The particles were resuspended via brief sonication. For lipofectamine
transfections, 6.4 µL of Lipofectamine 2000 (Life Technologies) reagent was
resuspended in 100 µL of OptiMEM (Life Technologies) at RT for 5 min. The
lipofectamine solution was then added to an equivalent volume of pDNA in
Optimem at a desired concentration for 20 min at RT. The lipid nanoparticle
solution was then added to each cell culture well at 10% of the working volume.
The CM containing lipid particles was aspirated and replaced with CM containing
antibiotics as stated above after 5 h.
3.5

Cytotoxicity.
Human embryonic kidney 293 cells (ATCC; 293T) were seeded at

approximately 30,000 cells/cm2, and, 24 h later, transfected with 1mg/mL of
particles and lipofectamine containing an equivalent pDNA dose as described
previously. Cell viability was determined 48 h post transfection by adding Celltiter
Blue reagent to each well at 10% of the culture volume. After 2 h, 90 µL of the
culture medium was transferred to a 96 well UV transparent plate (Corning) and
assayed for fluorescence at 560 nm excitation and 590 nm emission. The
fluorescent signal for each treatment group was normalized to the no treatment
(NT) group in order to determine viability. Toxicity was calculated as one minus
viability.
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3.6

Particle evaluation.

3.6.1 Nanoparticle characterization.
Scanning electron microscopy (SEM) was used to determine particle size
and morphology. Dried nanoparticles were applied onto double-sided carbon
tape and sputter coated with gold, under vacuum, for 30 s with a 40 mA current
(Dynavac Mini Coater, Dynavac, USA). An XL-30 ESEM-FEG (FEI Company)
having an acceleration voltage of 10 kV was used to visualize the nanoparticles.
The average particle size was determined using available image analysis
software (Image J, National Institute of Health). Particle hydrodynamic diameter
and surface charge was determined by dynamic light scattering on a Zetasizer
Nano ZS (Malvern Instruments, Ltd.).
3.7

CPT loading and in vitro release.
Polymer particles were dissolved at 1-10 mg/mL in dimethyl sulfoxide

(DMSO) for 1 h at RT. Afterwards, the dissolved particle solution was diluted 10
fold in CPT extraction buffer (EB; PBS containing 1% sodium dodecyl sulfate and
1% 1 N HCl v/v) for 1 h at RT. CPT was dissolved in DMSO at 5mg/mL and
diluted in CPT EB containing 10% DMSO (v/v) for the standard curve. Particle
and CPT samples in EB were added to a 96 well UV transparent plate and
evaluated for CPT fluorescence at 370 nm excitation and 428 nm emission.
Blank NP or MLNP fluorescence was subtracted from the drug sample signal and
evaluated for loading against the standard curve.
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To determine the CPT release characteristics, particles were suspended
in 1 mL of PBS at 3-6 mg/mL, placed in a 10 kDa snake skin dialysis tubing, and
sutured closed. The tubing was then placed into 15 mL conical tubes containing
10 mL PBS, which were loaded onto rotisserie shakers at 37C for 96 h. At
designated time points, 1 mL of the supernatant was aliquoted for subsequent
analysis and the remaining buffer was decanted. Ten mL of fresh PBS was
added to each tube after each collection. Thirty µL of EB containing 3.33%
DMSO (v/v) was added to 970 µL of sample. CPT was dissolved in DMSO at 5
mg/mL and diluted with EB containing 1% DMSO (v/v) for the standard curve.
Samples and standards were analyzed for CPT content as described above.
3.7.1 Plasmid loading and in vitro release.
MLNPs were dissolved at 2 mg/mL in DMSO for 1 h. The particle solution
was diluted 10 fold in Tris-EDTA (TE) buffer containing 12.5 mg/mL heparin
sulfate overnight at RT. Stock λ DNA was diluted in 12.5 mg/mL heparin sulfate
in TE buffer for the standard curve. Particle samples and standards were
transferred to a 96 well UV transparent plate, and combined with an equal
volume of Quant-iT PicoGreen reagent (Life Technologies) diluted in TE buffer
for 5 min at RT. Samples were assayed for fluorescence at 480 nm excitation
and 520 nm emission. Blank MLNP fluorescence was subtracted from the
plasmid sample signal and evaluated for loading against the standard curve.
Plasmid release characteristics were determined by resuspending 0.5
mg/mL particles in a 15 mL conical tube containing 10 mL of PBS. The tubes
were placed on a rotisserie shaker at 37C. At each time point, 1 mL of
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supernatant was aliquoted and replaced with 1 mL of fresh PBS. Each sample
was diluted 10 fold in TE buffer containing 12.5 mg/mL heparin sulfate overnight
at RT. Released plasmid content was measured using the Quant-iT PicoGreen
reagent as previously described.
3.7.2 PEI Loading and in vitro release.
MLNPs were dissolved at 2 mg/mL in 0.1 M sodium hydroxide (NaOH)
overnight at RT. PEI was dissolved in 0.1 M NaOH at 1 mg/mL and diluted for the
standard curve. Samples and standards were transferred to a 96 well UV
transparent plate, and 10 µL of 7 mg/mL fluorescamine in acetone was added to
each well (v/v 10:1) for 10 min at RT, and then assay for fluorescence at 390 nm
excitation and 475 nm emission. Blank MLNP fluorescence was subtracted from
the PEI sample signal and evaluated for loading against the standard curve.
PEI release characteristics were determined by resuspending 0.5 mg/mL
particles in a 15 mL conical tube containing 10 mL of PBS. The tubes were
placed on a rotisserie shaker at 37C. At each time point, 1 mL of supernatant
was aliquoted and replaced with 1 mL of fresh PBS. Each sample was diluted 10
fold in 0.1 M NaOH overnight at RT. PEI content was measured using the
fluorescamine reagent as previously described.
3.8

Functional evaluation.

3.8.1 Transfection analysis.
For the population transfection studies, MLNPs were loaded with pLuc (BL
MLNP), and 293T cells were transfected with 1 mg/mL MLNPs and an equivalent
plasmid dose using lipofectamine. Expression of luciferase was quantified using
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Luciferase Assay Reagent (LAR; Promega) 42 h post transfection. The CM was
aspirated, and cells were lysed using lysis buffer. After one freeze thaw cycle, the
lysates were spun down at 15,000 rpm for 3 min, 20 uL of supernatant was
added to 100 uL of LAR, and luminescence was measured using a Glomax
luminometer (Promega) over a 10 s integration period. Sample luminescence
was normalized to total sample protein, which was determined using a
bicinchoninic acid (BCA) protein assay (Thermo Scientific).
Percent cellular transfection was determined by loading MLNPs and lipid
NPs with pGFP towards transfecting 293T cells as above. Cells were imaged at
48-72 h post transfection using a Leica SP5 confocal microscope. Flow
cytometry analysis was performed by resuspending the 293T cells in PBS,
centrifuging once at 2,000 rpm for 3 min, and resuspending the pelleted cells in
Fluorescence-activated cell sorting (FACS) buffer. The resuspended cells were
then analyzed with a BD Biosciences FACScan to determine percent
transfection.
3.8.2 in vitro cytotoxicity.
The effect of CPT exposure and pTRAIL transfection timing on death
kinetics was determined in vitro using free CPT and pTRAIL delivered with
lipofectamine. Cells (U87, HCT116, and MDAMB231) were seeded in 96 well
culture plates (Corning) at 2,500 cells/cm2. All treatment groups were transfected
with pTRAIL 48 h after seeding, and exposed to CPT 24 h before (-24 h), during
(0 h), or 24 h after (+24 h) CPT exposure. Treatment controls included NT, and
CPT exposure alone at the respective time points. Treatment groups were
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analyzed for viability 48 h post transfection via Quant-iT Celltiter Blue reagent as
described earlier. Figure 11 illustrates the experimental design for the death
kinetics experiments.

Figure 11: Experimental design for evaluating camptothecin and TRAIL
plasmid transfection death kinetics.

MLNPs were then fabricated to deliver both CPT and pTRAIL as
described earlier (CT MLNPs). The initial loading of CPT in O1 ranged between
0.1 to 0.0001 mg/mL (CT1-3 or CL1-3, Table 8). U87, HCT116, and MDAMB231
cells were seeded in 96 well culture plates at 5,000 cells/cm2, and were
transfected with particles 24 h later. The doses of particles ranged from 3 mg/mL
to approximately 0.004 mg/mL, and cell viability was determined 72 h post
transfection using the Quant-iT Celltiter reagent as described earlier. CT2
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MLNPs, CL2 MLNPs, BT MLNPs, and CPT NPs were evaluated for efficacy in
reducing tumor growth in vitro.
3.8.3 Evaluating synergism.
The dose effect data comparing the fraction of tumor cells affected (Fa) to
drug or plasmid doses were analyzed using the Chou-Talalay analysis in order to
evaluate for synergism. Particle doses were converted to ug/mL of CPT or
pTRAIL according to particle loading characteristics. The data were analyzed
using the Compusyn software in order to determine Dm, CI, and DRI values as
detailed earlier (Equation 2-4).
3.8.4 Antitumor evaluation of MLNPs in vivo.
CT2 MLNPs, BT MLNPs, CL2 MLNPs, and BL MLNPs were fabricated as
described earlier, however, both mAP (1 mg/mL) and iRGD (0.25 mg/mL;
Thermo Scientific) were used in the final conjugation step. Male athymic nude
(NCr-nu/nu) mice were purchased from Taconic and maintained in a sterile
environment. All procedures were approved by the Institutional Animal Care and
Utilization Committee of Yale University. Tumors were established by injecting
mice with 2e106 HCT116 tumor cells subcutaneously. Experiments were started
when tumor volumes reached approximately 30-50 mm3. Mice were randomly
divided into groups of three to six mice per treatment group as follows: group 1,
PBS control; group 2, CT2 MLNP; group 3, CL2 MLNP; group 4, BT MLNP;
group 5, BL MLNP. Each mouse was injected with 1.5 mg of particles via tail vein
three days a week until the end of the experiments. Each injection consisted of
100 µL of 1 mg/mL particles in PBS. Tumor size was measured using traceable
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digital vernier calipers (Fisher). The tumor length (l) and the width (w)
measurements were obtained in order to calculate tumor volume (V =1/2*lw2).
The growth curve was plotted with respect to tumor volumes. The animals were
killed two days after tumors grew over 1 cm3, excised, and formalin-fixed for
immunohistochemistry. Slides of serial sections were stained with TUNEL for
analysis of therapeutic effects.
3.9

Statistical analysis.
For all in vitro studies, test groups were conducted in replicates of three, and

compared using a two-sample heteroscedastic t-test. One-way ANOVA analysis
was performed to determine the statistical significance of treatment-related
changes for the in vivo studies. A p value smaller than 0.05 was considered to be
significant for all analyses. All error bars denote the standard error for each
group.

4 Results
4.1

Nanoparticle fabrication.

4.1.1 Surface modifications and biotoxicity.
Changes in particle morphology and size were analyzed during each step
of the MLNP fabrication protocol. Figure 12 displays SEM images of the MLNPs
at different fabrication stages. Sequential surface modification of PLGA particles
with PEI and pDNA did not alter particle size or morphology as all particles were
spherical with average dry diameters between 113-123 nm. Table 7 lists the
measurements for both the dry and hydrodynamic particle diameters in addition
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to surface charge, PEI loading, and plasmid loading. The initial surface
complexation of PLGA particles with PEI (PLGA-P) did increase particle surface
charge from -23.3 mV to 32.3 mV with a total load of 3.7 ug of PEI per mg of
particle(Figure 13). There was a relative decrease in surface charge and a
minimal drop in PEI content with subsequent surface condensation of pDNA
(PLGA-PD). The second layer of PEI increased the total content to 44.5 ug of
PEI per mg particle with a concomitant increase in surface charge to 26.6 mV
(PLGA-PDP). Conjugation of mAP to the outer PEI layer via an heterobifunctional
PEG cross-linker did not alter surface charge dramatically, however, there was a
relative drop in total PEI content with each conjugation step(Figure 13). Cell
proliferation was measured using the Celltiter Blue assay, and viability was
determined by normalizing the signal to groups receiving NT. Toxicity was
calculated by subtracting viability from one. Initial surface modification with PEI
(PLGA-PD) rendered particles significantly toxic to cells (Figure 14). Only after
conjugation with PEG-mAP did particle toxicity decrease significantly.
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Figure 12: The effect of surface modification on particle size.
Figure 12A contains a different length scale.
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Figure 13: The effect of surface modifications on particle surface charge
and polyethyleneimine (PEI) loading.
P – PEI, D – pDNA

Figure 14: The effect of surface modifications on particle toxicity.
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4.2

Particle evaluation.

4.2.1 Loading and release studies.
PEI and plasmid loading of the MLNPs after each fabrication step is listed
in Table 7. The particles analyzed in Table 7 were all prepared with EA as the
organic phase. There is a decrease in plasmid content with each fabrication step,
and the final MLNP plasmid load was approximately 575 ng per mg of particle.
CPT encapsulation within MLNPs was tunable relative to initial CPT loading
(Table 8). Decreasing the initial CPT load from 0.1 mg CPT per mg PLGA (CT1
MLNP) to 0.001 mg CPT per mg PLGA (CT2 MLNP) resulted in an approximately
10 fold decrease in loading to approximately 0.018-0.071 µg/mg, with minimal
change in loading efficiency. Decreasing the initial CPT load even further to
0.0001 mg CPT per mg PLGA (CT3 MLNP) resulted in a decrease in loading to
approximately 0.006-0.010 µg/mg while maintaining a similar loading efficiency.
Using DCM as the organic phase resulted in similar CPT loading trends. There
was batch to batch variability in loading which is detailed in Table 8. Surface
modification did not alter CPT release profiles(Figure 15A). CPT release and PEI
dissociation from CT2 MLNPs prepared with EA occurred readily, achieving 8090% release within 24 hours (Figure 15B). Plasmid release lagged behind CPT
release, and approximately 80% of the total plasmid amount was released within
48 hours.
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Table 7: Particle characteristics.
PARTICLE

SEM
DIAMETER
(nm)

PLGA

122.7 +/24.7

PLGA-P
PLGA-PD
PLGA-PDP
PLGAPDP-PEG
PLGAPDP-PEGmAP

113.6 +/26.6
122.8 +/24.7
108.6 +/25.8
116.4 +/24.7

ZETA
PARTICLE
DIAMETER
(nm)

SURFACE
CHAGE (mV)

PEI
LOADING
(ug/mg)

PLASMID
LOADING
(ug/mg)

-23.3 +/- 2.27

--

--

193.1 +/- 2.7

32.3 +/- 1.01
20.6 +/- 1.9

3.7 +/- 0.6
3.3 +/- 1.5

-2.70 +/- .009

198.4 +/- 1.8

26.6 +/- 6.5

44.5 +/- 0.2

2.86 +/- .006

31.1 +/- 5.1

27.9 +/- 1.0

2.14 +/- .112

28.2 +/- 2.0

24.2 +/- 0.1

0.575 +/- .045

206.1

Table 8: Camptothecin encapsulation.
CPT LOADING (MG CPT/

MLNP CPT ENCAPSULATION

LOADING

MG POLYMER)

(MG CPT/MG PLGA)

EFFICIENCY (%)

CT1

0.1

2.900e-3

2.9

CT2

0.001

0.018e-3 to 0.071e-3

10

CT3

0.0001

0.006e-3 to 0.010e-3

2.0
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Figure 15: Particle release profiles.
4.3

Functional evaluation.

4.3.1 Cellular transfection.
Luciferase activity in 293T cells was measured 48 hours post transfection
with MLNPs and lipofectamine. Surface modification with PEI and pLuc (PLGA-
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PD, PLGA-PDP) allowed for transfection of 293T cells(Figure 16A). Further
modification with 5kDa PEG and mAP (PLGA-PDP-PEG-mAP) resulted in
greater luciferase activity after transfection. However, in these initial formulations,
lipofectamine still provided greater transfection than the MLNPs. Transfection
was subsequently improved by utilizing a lower molecular weight PEG (1kDa)
and co-encapsulating TCHD (Figure 16B). Preparing particles with EA instead of
DCM in the organic phase improved MLNP transfection levels resulting in
luciferase activities after transfection that was comparable to lipofectamine. The
optimal MLNPs were those fabricated using EA, 1kDa PEG, and TCHD.
Subsequent transfection of 293T cells at lower seeding densities with these
MLNPs resulted in significantly greater luciferase activity than
lipofectamine(Figure 16C). To identify the fraction of cells that were successfully
transfected, the percent cell transfection was determined by measuring GFP
expression via confocal microscopy and flow cytometry. Figure 17 displays
fluorescent images of 293T cells taken 48 hours (Figure 17A,C) and 72 hours
(Figure 17B,D) post transfection with MLNPs and lipofectamine carrying pGFP.
The fluorescent signal for the MLNP groups increased from 48-72 h, however,
the signal from the lipofectamine groups decreased over this period. Transfected
cells were analyzed using flow cytometry at 72 hours post transfection to
determine percent cellular transfection. MLNP percent cellular transfection was
measured at 37% compared to 58% obtained by lipofectamine (Figure 18). A
clear shift in the FL1 peak could be observed for the MLNP group but was not
apparent in the lipofectamine group. Total cell number was greater for the MLNP
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groups than the lipofectamine groups at both 48 and 72 hours post transfection,
and can be visualized on the confocal images(Figure 17).

Figure 16: Population transfection optimization.
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Figure 17: Green fluorescent protein expression after particle transfection.
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Figure 18: Percent cell transfection.
4.3.2 in vitro cytotoxicity.
Before evaluating MLNPs for combination in vitro drug and gene delivery,
cell death studies were conducted on U87, HCT116, and MDAMB231 cell lines to
determine optimal timing of CPT exposure and pTRAIL transfection(Figure 19).
Exposure to CPT concurrently with pTRAIL transfection resulted in the greatest
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relative decrease in viability for all cell lines. Transfection with seven ng/well of
pTRAIL resulted in significant decreases in cell viability with concomitant therapy.
HCT116 cells demonstrated the largest relative decrease in cell viability with CPT
and pTRAIL gene therapy(Figure 19B). MLNPs loaded with both CPT and
pTRAIL (CT MLNP) were tested for efficacy in reducing tumor cell proliferation in
vitro(Figure 20). CT MLNPs were fabricated with increasing pTRAIL to CPT
loading ratios. All particles contained approximately 575 ng of pTRAIL per mg of
PLGA, and were loaded with decreasing CPT content as detailed in Table 8.
After exposing cells to an effective 0.01 µM dose of CPT via MLNPs, CT 2
MLNPs resulted in the greatest effect on reducing HCT116 tumor growth in
vitro(Figure 20). The CT2 MLNP formulation was then used for subsequent
synergy analysis, which delivered a ratio of pTRAIL to CPT of 31.8.
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Figure 19: Tumor death kinetics relative to camptothecin exposure and TNF
related apoptosis inducing ligand plasmid transfection.
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Figure 20: The effect of multi-layered nanoparticle loading and cell death.

Table 9: Camptothecin to TNF related apoptosis inducing ligand ratio.
CPT:pTRAIL RATIO
pTRAIL dose (ng/well)

25 nM CPT

2.5 nM CPT

7.000

0.128

0.036

3.500

0.257

0.071

1.750

0.514

0.142

0.875

1.029

0.285

Table 10: Camptothecin to TNF related apoptosis inducing ligand ratio for
multi-layered nanoparticle formulations.
FORMULATION

CPT:pTRAIL RATIO

CT1

5.00

CT2

0.03

CT3

0.01
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4.3.3 Evaluating synergism.
Delivering CPT and pTRAIL via MLNPs shifted the dose effect curves to
the left for all cell lines(Figure 21). Figure 21A and B compare the dose effect
curves of CT2 MLNPs to CPT MLNPs containing the pLuc plasmid (CL2 MLNPs)
and CPT NPs respectively on all cell lines. Figure 21C illustrates the dose effect
curves comparing CT2 MLNPs and blank MLNPs loaded with pTRAIL (BT
MLNPs). Chou-Talalay analysis of CT2 MLNPs compared to CL MLNPs and BT
MLNPs as well as CPT NPs and BT MLNPs were performed, and the CI and DRI
for both CPT and pTRAIL can be seen in Figure 22 and Figure 23 for all Fa
levels. Table 12 and Table 13 provide the CI and DRI values at a Fa of 50% in
addition to the Dm for each agent. The linear regression coefficients for fitting the
dose effect data to the MEE transformation (Equation 2) were above 0.90 for all
dose affect curves(Table 11). CompuSyn analysis on all cell lines produced CI
values that were predominantly between 0.3 and 0.7(Table 6).
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Figure 21: Dose Effect curves.
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Figure 22: Chou-Talalay synergism analysis of CT2 MLNPs compared to
CL2 MLNPs and BT MLNPs.
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Figure 23: Chou-Talalay synergism analysis of CT2 MLNPs compared to
CPT NPs and BT MLNPs.

Table 11: Goodness of fit of the Chou-Talalay analysis.
DOSE AFFECT CURVE

CHOU-TALALAY LINEAR REGRESSION COEFFICIENT
U87

HCT116

MDAMB231

CL2 MLNP

0.98

0.92

0.97

CPT NP

0.94

0.97

0.94

CT2 MLNP

0.98

0.99

0.99

BT MLNP

0.94

0.94

0.99
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Table 12: Combination index, dose-reduction index, and median effect dose
for CT2 MLNPs and CL2 MLNPs.
CT2 MLNP

CPT Dm (nM)

CELL LINE

CI

CPT DRI

pTRAIL DRI

CT2 MLNP

CL2 MLNP

U87

0.53

3.14

4.66

19.7

43.4

HCT116

0.45

3.51

6.09

7.15

17.6

MDAMB231

0.33

7.38

5.01

19.4

263

Table 13: Combination index, dose-reduction index, and median effect dose
for CT2 MLNPs and CPT NPs.
CT2 MLNP

CPT Dm (nM)

CELL LINE

CI

CPT DRI

pTRAIL DRI

CT2 MLNP

CPT NP

U87

0.39

5.80

4.66

19.7

107

HCT116

0.35

5.43

6.09

7.15

33.7

MDAMB231

0.33

7.38

5.01

19.4

281

4.3.4 Antitumor evaluation of MLNPs in vivo.
The initial results of the in vivo therapeutic study are presented in Figure
24. Average tumor volumes are shown in figure, and there is a decrease in tumor
growth for both the BT MLNPs and CT2 MLNPs treatment groups. This
experiment is currently ongoing.
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Figure 24: in vivo antitumor effects of MLNPs.

5 Discussion
5.1

Nanoparticle fabrication and characterization.
Multifunctional PLGA nanoparticles were synthesized for the simultaneous

delivery of CPT and pDNA. CPT was loaded into the core of PLGA nanoparticles,
which were subsequently surface modified to facilitate electrostatic complexation
with pDNA. Surface modifications of PLGA nanoparticles were implemented by
utilizing established conjugation chemistries. Figure 10 illustrates the step by
step surface modifications involved in fabricating the MLNPs. The PLGA polymer
used for making the particle core is carboxy terminated, and the pKa values of
the acid groups on PLGA are 3.86 and 3.83156. Therefore, the multiple positively
charged amines on the PEI dendrimers will complex with the negative carboxyl
end groups(Figure 10C-D) during precipitation in W2. Although, there may PEI
within the particle, creating a PLGA-PEI blend, the majority of the polymer PEI
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will likely be on the surface due to hydrophilic interactions. The surface PEI
coating contains multiple primary, secondary, and tertiary amines with pKa
values ranging from 4.5, 6.7, and 11.6 respectively157. PEI is well known for its
ability to form electrostatic complexes with pDNA. In this case, the condensation
of plasmid DNA and the second PEI layer was conducted at pH 4 to ensure
protonation of all of the amine groups(Figure 10E-H), so that the greater positive
charge of PEI can facilitate electrostatic coupling between the protonated amines
and negative phosphate backbone of DNA. Heterobifunctional PEG molecules
were then conjugated to the amine groups on PEI (Figure 10I-J). The PEG crosslinker contained terminal NHS and maleimide groups. NHS is a highly stable
leaving group which facilitates amide bond formation with the amines on PEI
through a SN2 reaction. Subsequently, the maleimide end group readily reacts to
thiol groups, like those found on cysteine terminated mAP, forming thioether
bonds (Figure 10J-L). Each surface modification step was performed with a
molar excess of conjugating reagents.
The modular design of the MLNP provides the capacity for alternative
functionalization given the requirements for the delivery system. The mAP ligand
could be replaced with other CPPs or targeting ligands in order to increase
localization and uptake at the desired tissue site. These MLNPs utilized
maleimide thiol conjugation chemistry to attach mAP to the outer surface.
However, other conjugation protocols can be utilized to attach CPPs, ligands, or
antibodies. PEG cross-linkers can be terminated with a variety of functional
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groups other than NHS and maleimide, allowing for potential conjugation with a
variety of compounds.
Functionalizing core PLGA particles with multiple layers of PEI allowed for
loading of pDNA in addition to encapsulating our candidate small molecule, CPT.
Particle diameter remained constant at approximately 115 nm after surface
modifications (Table 7), which is beneficial for passive targeting since the ideal
particle size for utilizing the EPR effect is between 10 to 200 nm. Surface
attachment of PEI was successful, as indicated by a change in surface charge
from -23.3 mV to 32.3 mV, and a PEI load of 3.7 ug/mg of particle (Figure 13).
The ability to condense DNA onto the particle is due to electrostatic condensation
onto the positively charged PEI coating. As expected, the condensation of
negatively charged DNA decreased the surface potential. Subsequent addition of
another layer of PEI increased the surface potential again to values ranging from
26.6 to 31.1 mV. The bulk of the total particle PEI content appears to be located
in the second layer as the total weight normalized PEI load increased
substantially, from 3.7 ug/mg to 44.5 ug/mg, with the addition of the second layer.
There was a measurable decrease in PEI content with each subsequent
conjugation, which is likely due to partial dissociation of the outer PEI layer with
each conjugation and centrifugation steps. A similar effect was observed on total
plasmid content, as the initial weight normalized plasmid load of 2.7 ug/mg
decreased to approximately 575 ng/mg after the final modification step. The
sequential conjugation of PEG and mAP to the MLNP surface was performed at
pH 7.4. At a neutral pH, the primary and secondary amines on PEI are
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deprotonated, which destabilizes the electrostatic coupling with DNA. After
centrifugation, the resulting pellet was sonicated in order for re-dispersion of
particles into solution. The sonication energy may also cause shedding of PEI
and pDNA from the particle. Although electrostatic coupling does allow for facile
plasmid loading, there is a measurable inefficiency resulting from partial PEI and
DNA loss with each conjugation step. As a result, the final plasmid dose is
approximately 21% of the initial plasmid load.
Surface coating with PEI did render the particles highly toxic to 293T cells,
which may be due to the interactions of surface PEI with the cellular
membrane(Figure 14). Coating with PEG-mAP likely hindered these cytotoxic
interactions, which significantly decreased toxicity to levels much lower than
lipofectamine.
PLGA particles readily encapsulate CPT due to the hydrophobic nature of
the molecule. Previous studies analyzing CPT encapsulation into PLGA
nanoparticles demonstrated high loading efficiencies133. Similarly, MLNPs were
able to encapsulate CPT at high loading efficiencies (data not shown); however,
co-encapsulation with TCHD did decrease CPT loading efficiencies. Double
emulsion protocols are inherently less efficient for drug loading, which was
required for co-encapsulating TCHD since it is a hydrophilic molecule. However,
our goal was ultimately to deliver less CPT, and therefore decreased loading
efficiencies were not a significant disadvantage for this particular application. In
fact, delivering a greater ratio of pTRAIL to CPT was preferred. Particle loading
was therefore decreased by reducing the initial CPT dissolved in the organic
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phase of the emulsion procedure. Table 8 demonstrates that decreasing the
initial CPT load per mg of PLGA resulted in reduced final MLNP loading.
CPT was readily released from MLNPs as approximately 80% was released
within twelve hours. Surface modifications did not alter the drug release profile
(Figure 15). The outer PEI layer readily dissociated from the particle as well, with
80% of the total PEI content being released within twelve hours. There was a lag
in plasmid release since it required 48 hours for 80% of the total plasmid load to
be released from the MLNPs. This may suggest that the majority of the plasmid
is complexed with the first PEI layer. The in vitro release studies were performed
in buffered saline at physiologic pH. However, the tumor microenvironment and
the endosomal compartment are acidic, which may influence particle release
profiles. Additionally, plasmid release analysis was conducted in high levels of
heparin to promote plasmid dissociation from PEI in order for subsequent
measurement with the picogreen assay. Plasmid dissociation in vivo will likely be
more prolonged, which may be beneficial for protecting plasmids from both
circulating and cytosolic endonucleases.
5.2

Transfection evaluation.
The initial goal was to improve MLNP transfection capabilities. Population

transfection studies were conducted by delivering pLuc to 293T cells via MLNPs.
As displayed in Figure 16, optimizing particle fabrication parameters resulted in
high 293T transfection levels that were ultimately comparable to lipofectamine.
PEI has already demonstrated to be a potent transfection vehicle, but is also
known to be highly toxic to cells. After coating the outer PEI layer with PEG-mAP,
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transfection levels measured by luciferase activity increased (Figure 16), which
was partly a result of the significant decrease in particle toxicity(Figure 14).
These effects may be due to the inhibition of PEI associated membrane
disruption and apoptosis with PEG conjugation. The transfection levels, however,
were still significantly lower than lipofectamine. In addition to coating the PEI and
minimizing particle toxicity, utilizing a PEG heterobifunctional linker allows for
subsequent functionalization with a CPP. For the in vitro studies, mAP was used
to improve cellular transfection since previous studies have demonstrated
superior transfection capabilities associated with particles functionalized with
mAP compared to other CPPs54. Surface conjugation with mAP provided similar
results of significantly improving transfection capabilities.
The first optimization studies (Figure 16A) used a 5 kDa PEG cross-linker.
Decreasing the molecular weight of PEG has been shown to increase particle
transfection, and recent studies suggest 1 kDa PEG molecules were most
optimal158. MLNPs conjugated with a 1 kDa PEG cross-linker resulted in greater
transfection levels (Figure 16B). Decreasing PEG size may allow for a greater
number of PEG units to bind to the PEI coating, which then provides more
maleimide groups for conjugating mAP. TCHD was also co-encapsulated into the
PLGA core in order to improve gene transfection. TCHD increases nuclear pore
patency, which permits plasmid localization into the nucleus. Incorporation of
TCHD increased transfection levels by a factor of 2-5. Finally, switching the
organic phase from DCM to EA improved particle transfection. Theoretically, this
effect is due to the smaller size of the particles. EA diffuses out of the PLGA
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precipitant upon exposure to the aqueous phase, which favors formation of
smaller particles due to faster hardening of the particles. MLNPs particles
fabricated with EA, TCHD, and 1 kDa PEG provided the greatest transfection
levels, which were comparable to lipofectamine(Figure 16B). The transfection
results displayed in Figure 16A-B were conducted on cells seeded at
approximately 50,000 cells/cm2. Figure 16C demonstrates that decreasing the
seeding density can increase normalized population transfection levels. This may
be related to the greater amount of particles per cell at lower seeding densities.
Additionally, the fraction of mitotically active cells may be greater at lower
densities since higher seeding densities result in confluency earlier. This can in
turn result in greater particle internalization within the dividing cells. MLNPs are
more likely to be internalized in mitotically active cells, due to the increased
probability for random localization within the cytosol or even the nucleus. The
method of transfection with lipid particles differs, since internalization primarily
occurs after particle fusion with the plasma membrane. Lipofectamine solutions
are removed at approximately four hours post transfection due to cellular toxicity,
which limits their potential for internalization in dividing cells. The greater toxicity
of lipofectamine may also have a greater effect on cell growth, especially at lower
seeding densities. The MLNPs remained in the cell culture medium since they
are non-toxic.
Percent cell transfection was then determined by transfecting 293T cells
with pGFP. GFP expression in individual cells can be visualized through confocal
microscopy and quantified using flow cytometry. Figure 17 provides fluorescent
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images of GFP expression 48 and 72 hours post transfection with MLNPs (Figure
17A and B respectively), and with lipofectamine (Figure 17C and D respectively).
The percentage of cells transfected is higher with lipofectamine, however, there
was a clear shift in the fluorescence peak for the MLNP group (Figure 18).
Percent transfection is dependent on total viable cells, which is fewer in the
lipofectamine groups due to particle toxicity. The fewer viable cells in the
lipofectamine group may explain why the population transfection levels are
similar to the MLNP group despite having a greater percent transfection.
Additionally, the MLNP transfected cells may be expressing higher levels of the
transgene due to the decreased toxicity of the particle. However, these cells
should theoretically be producing a greater amount of total protein as well, which
is incorporated in the normalized values. GFP transgene expression was also
more stable over time in the MLNP group as GFP signal decreased over time in
the lipofectamine group. In contrast to the lipid particles, MLNPs gradually
release their DNA cargo (Figure 15), which will effect long term transgene
expression levels. This property is typically better for in vivo applications since it
protects the genetic material from endonucleases for extended periods of time. It
is likely that a combination of factors is affecting population transfection levels.
5.3

in vitro cytotoxicity.
As described earlier (Figure 8), there are multiple mechanisms for cross talk

between the apoptotic stimulus provided by CPT and TRAIL. The evidence of
synergism between TRAIL and multiple chemotherapeutics including CPT is
growing. There are a few clinical trials (NCT00671372, NCT00508625)
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evaluating the efficacy of recombinant human TRAIL protein and multiple
chemotherapeutics. Previous nanoparticle research evaluating the delivery of
either CPT or TRAIL therapy is promising. However, there are no studies
evaluating the efficacy of combination CPT and TRAIL therapy via a nanovector.
Further, there has yet to be any evaluation of the effect of CPT and TRAIL gene
therapy in animals. In many forms of gene therapy for cancer, cell transfection
efficiency is important since it is theoretically necessary to knockdown gene
expression in every cancer cell. Even with the most potent transfection vector,
100% gene transfection is an extremely challenging goal. However, with pTRAIL
transfection, 100% transfection is not required for therapeutic efficacy.
Transfected cells can express and secrete TRAIL, and through the bystander
effect, neighboring, non-transfected cells, are still subjected to apoptosis by
activation of extrinsic death receptors149. It is unclear if either DR4 or DR5 have
cytosolic binding sites for TRAIL. The dominant mechanism of cell death,
whether it occurs internally through TRAIL signaling or externally through TRAILDR interactions, needs further investigation.
Cancer cell lines have variable sensitivities to CPT and TRAIL. The in vitro
cytotoxicity screens evaluated the efficacy of combination therapies on U87,
HCT116, and MDAMB231 cells. Previous studies analyzing the effect of
combination CPT and the TRAIL peptide suggest that pretreatment with CPT
sensitizes cancer cells to TRAIL mediated apoptosis. Due to the lag between
transfection and protein expression, the death kinetics of CPT and pTRAIL
transfection were studied to determine the optimal timing for each therapy. Figure
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19 compares the efficacy of reducing tumor growth in vitro with combination CPT
delivery and pTRAIL transfection via lipofectamine. Subtherapeutic doses of CPT
and pTRAIL were used in order to appreciate the effect of combination delivery.
U87 and MDAMB231 cells were exposed to 25 nM CPT (Figure 19A and C).
Since HCT116 cells are more sensitive, they were exposed to 2.5 nM CPT
(Figure 19B). Combination therapies were normalized to groups receiving a
similarly timed CPT dose in order to determine the relative increase in tumor cell
death. The resulting death kinetics suggest that CPT exposure during or before
TRAIL transfection provided the greatest reduction in tumor cell growth. The
most significant effect was seen with CPT delivery during transfection for all cell
lines. Transgene expression usually occurs 24-48 hours after transfection, which
coincides with previous timing experiments with combination CPT and TRAIL
peptide therapies. These results add further support to the theory that CPT
exposure sensitizes cells to TRAIL, by either up-regulating DR4 and DR5
expression, or inhibiting Bcl-2 activity(Figure 8)155,159. Furthermore, we can
deliver CPT and pTRAIL at the optimal timing by using the MLNP delivery system
(Figure 15B). If other drug and gene formulations were to be evaluated, drug
release can be tuned by adjusting LA and GA monomer ratio of PLGA if slower
or faster release was desired. A greater delivery of pTRAIL to CPT resulted in the
most significant effects (Table 9 and Figure 19). The greater relative increase in
cell death for the HCT116 groups when compared to the U87 and MDAMB231
groups is likely due to the smaller CPT to pTRAIL dose.
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The next goal was to design CT MLNPs that effectively delivered the largest
ratio of pTRAIL to CPT. In order to evaluate the efficacy of MLNPs in reducing
tumor growth, pTRAIL was loaded onto CPT encapsulated MLNPs (CT MLNP).
CPT is a potent anti-cancer agent, and delivering a greater ratio of CPT to
pTRAIL will provide overwhelming toxicity primarily due to CPT activity.
Therefore, multiple MLNP formulations with varying CPT to pTRAIL loading ratios
were fabricated (Table 8). Each formulation was evaluated for its effect on
inhibiting HCT116 growth in vitro(Figure 20). The CT MLNP groups provided an
effective 0.01 uM dose of CPT. MLNPs with lower drug loading will therefore
deliver a greater plasmid dose since more particles were delivered to meet the
required CPT dose. The optimal formulation was CT2. Since PEI is a base, it
may contribute to inactivation of CPT via lactone hydrolysis(Figure 9). Although
CT3 MLNPs delivered more pTRAIL per molecule of CPT (Table 10), they also
provided more PEI, which could potentially reduce the efficacy of CPT. The CT2
formulation delivered a ratio of CPT to pTRAIL of approximately 0.03 which is
smaller than the ratio of CPT to pTRAIL doses used in the death kinetics
experiments.
5.4

Analysis of synergism.
Dose effect curves were then obtained for CT2 MLNPs, CL2 MLNPs, CPT

NPs, and BT MLNP on inhibiting U87, HCT116, and MDAMB231 cell growth in
vitro. There was a strong left shift in the dose effect curves of CT2 MLNP when
compared to both CPT NPs, CL2 MLNPs, and BT MLNPs for all cell lines. The
CPT Dm was significantly lower when using the CT2 MLNP formulation.
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Modelling the data using the linearized MEE (Equation 2) resulted in correlation
coefficients greater than 0.9 for all curves indicating a goodness of fit of the linear
regression, and validating the use of the Chou-Talalay analysis for assessing
synergism between CPT and pTRAIL when delivered via MLNPs. The CI values
were less than one for almost all Fa levels. Specifically, the majority of both
experiment and theoretical CI values were between 0.3-0.7 for all cell lines which
suggests a synergistic interaction(Figure 22 and Figure 23). The CPT DRI at Fa50
ranged from 3.14-7.38 for CPT and 4.66-6.09 for pTRAIL. The actual CPT dose
along with specific Fa50 DRI and CI values for each cell line are listed in Table 12
and Table 13. The lower CPT DRI for HCT116 and U87s may be due to the
increased sensitivity of this cell line to CPT compared to MDAMB231s.
The in vitro synergy analysis not only supports the efficacy of co-delivering
CPT and pTRAIL for reducing tumor cell growth, but it also validates the use of
MLNPs for co-delivery of the two agents. This is the first successful in vitro
analysis of synergism for a nanoparticle delivery system providing combination
therapy. The resulting DRI values for the CT2 MLNP formulation suggests that
we can deliver a dose that is approximately order of magnitude lower via
combination delivery. This can potentially result in safer treatment regimens
through decreasing system toxicities. Additionally, certain drugs have lower
encapsulation efficiencies in PLGA nanoparticles. Combination therapies can
potentially improve therapeutic efficacy for other cancer chemotherapeutics
because they decrease the required dose for effectiveness.
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5.5

Antitumor evaluation of MLNPs in vivo.
The preliminary in vivo evaluation of the therapeutic efficacy for

combination gene and small molecule therapy demonstrates a greater antitumor
effect of CT2 MLNPs when compared to both CL2 MLNPs and BT MLNPs.
Definitive conclusions cannot me made at this time, as it is still early in the tumor
growth curve. The therapeutic study is ongoing, and tumor size and mouse
weight will be monitored for several more days.
5.6

Conclusion.
Nanoparticles provide exciting avenues for addressing current obstacles in

cancer chemotherapy. As discussed, most chemotherapeutic agents have
inherent risks, and limitations in efficacy. Nanoparticles can provide a stable
vehicle for targeted delivery in order to reduce systemic toxicities. Further,
utilizing these vectors for combination, multi-modal therapy allows for minimizing
drug resistance and improving efficacy. Tumors are highly heterogeneous, and
so the necessity for personalized medicine and the ability to deliver multi-modal
therapy is important. It is necessary to design nanocarriers to utilize synergistic
agents in order to increase their potency, and allow for decreased dosing.
Although, there have been considerable improvements in particle transfection
capabilities, their efficiency is much lower than viral vectors. Particles that
demonstrate high transfection capabilities, including most lipid particles, are both
toxic and unstable. Additionally, co-delivering small molecules with genetic
material via nanoparticles has been inefficient. MLNPs show promise in providing
a delivery vehicle for tunable small molecule encapsulation and release as well
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as high gene transfection potential. The results support our hypothesis that
delivering multiple therapeutic agents using MLNPs can provide improved antitumor effects when compared to monotherapy. The in vitro studies showed
tunable anti-tumor effects of co-delivering TRAIL plasmid and CPT. Additionally,
co-delivery with MLNPs showed a synergistic inhibition of tumor growth in vitro,
and preliminary in vivo evaluation of their antitumor effects are promising. Future
nanoparticle formulations for combination therapies should also be analyzed in
vitro for synergism prior to in vivo evaluation. The MLNP’s modular,
multifunctional design provides a robust system for efficiently delivering both
small molecules and gene therapy, and create an attractive vehicle for
combination anti-cancer therapies.
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7 Figures
Figure 1: Relative sizes of nanoparticles compared to common biological
structures.
Illustration of nanoparticle size as compared to common biological structures and
their associated length scale. An electron microscope is needed to visualize
structures that are submicron in size.
Figure 2: Hydrolysis of poly(lactic-co-glycolic) acid.
The chemical structure of poly(lactic-co-glycolic) acid and its hydrolytic
breakdown into biocompatible metabolites.
Figure 3: Distribution coefficient of common anti-neoplastic agents.
The frequency distribution of anti-neoplastic agents by lipophilicity. The
distribution coefficient (D) is a measure of lipophilicity, and log(D) values greater
than zero indicate greater solubility in oil rather than water. The majority of
clinically available anti-neoplastic agents are lipophilic.
Figure 4: Nanoparticle pharmacokinetics.
Drug plasma concentrations associated after repeated free drug boluses
compared to a single nanoparticle dose. Due to rapid bioavailability and
clearance of free drugs relative to drug encapsulated polymer nanoparticles,
plasma concentrations (blue line) will oscillate above and below the maximum
tolerated concentration (MTC) and minimum effective concentration (MEC).
Plasma drug levels above the MTC will result in systemic toxicity whereas drug
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levels below the MEC will be ineffective. Drug loaded polymer nanoparticles
theoretically release drugs via first order rate kinetics resulting in a more stable
plasma drug level.
Figure 5: Mechanism for iRGD binding and penetration57.
The mechanism for internalizing RGD (iRGD) binding and penetration into the
endothelium of tumor vasculature. The process includes binding of the RGD
motif to the αvβ3/αvβ5 integrins that are up regulated on tumor endothelial cells.
The peptide is then cleaved by proteases, which expose the CendK/R element
allowing for subsequent binding to neuropilin-1 and penetration into the tumor
tissue.
Figure 6: Pathways for endocytosis.
The multiple endocytic pathways and their associated biophysical properties.
Each pathway has characteristic compartment sizes, molecular players, and
intracellular fates. Certain targeting moieties can be utilized to target specific
endocytic pathways, and common examples are provided. AP – antennapedia,
CDC42 - cell division cycle 42, CLIC-D - dynamin-dependent clathrinindependent carriers, CLIC-DI - dynamin- and clathrin-independent carriers, ER –
endoplasmic reticulum, RGD - arginine-glycine-aspartic acid, TAT –
transactivator of transcription, TGN – trans-Golgi network, TK – Tyrosine
kinases.
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Figure 7: Barriers to gene therapy.
The six major barriers for gene delivery. Gene loaded particles need to be stable
and need to protect their genetic cargo during transport in the circulatory system,
while ultimately being able to localize at the target tissue (1). After penetrating
the tissue vasculature, there needs to be efficient uptake of the particle into the
cell (2). After endocytosis, the particle needs to effectively escape the endosome
(3) and transfer into the nucleus (4). Once inside the nucleus, the transgene
needs to persist and maintain adequate transcriptional activity (5). During the
entire process, these particles will need to evade the host immune response (6).
CTL – cytotoxic T lymphocyte, L – lysosome, V – vesicle. R – endosomal
recycling, T – transcytosis.
Figure 8: Apoptosis signaling cascade.
The intrinsic and extrinsic regulatory pathways of caspase mediated apoptosis.
Intrinsic stress, including genetic instability from cytotoxic chemotherapeutics like
camptothecin (CPT), and extrinsic death receptor signaling can increase
apoptosis via caspase activation. Activating both pathways can potentially
overcome resistance due to mutations in TP53. Growth receptor signaling
decreases caspase activation, and can be a target for anti-neoplastic therapies.
Figure 9: Reversible hydrolysis of camptothecin.
Camptothecin can be reversibly hydrolyzed from the active lactone form into the
inactive carboxylate form. Acidic conditions favor the close lactone form, whereas
basic conditions favor lactone opening.
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Figure 10: Surface modification of multi-layered nanoparticles.
Schematic for the step-by-step fabrication and surface modifications of multilayered nanoparticles (MLNPs). A-B. Camptothecin was encapsulated into
poly(lactic-co-glycolic) (PLGA) nanoparticles. C-D. The PLGA nanoparticles were
complexed with polyethyleneimine (PEI) which results in a net positive surface
charge on the MLNPs. E-F. Plasmid DNA was then complexed onto the positive
surface of the MLNPs. G-H. Another layer of PEI was subsequently complexed
onto the MLNPs. I-J. A heterobifunctional polyethylene glycol (PEG) linker was
then conjugated to the outer PEI layer. K-L. Finally, a cell penetrating peptide,
specifically modified antennapedia, was conjugated to the PEG linker.
Figure 11: Experimental design for evaluating death kinetics associated
with camptothecin exposure and TRAIL plasmid transfection.
The experimental design for determining death kinetics after camptothecin (CPT)
exposure and TNF related apoptosis inducing ligand plasmid (pTRAIL)
transfection. Cells (U87, HCT116, and MDAMB231) were seeded in 96 well
culture plates at 2,500 cells/cm2. All treatment groups were transfected with
pTRAIL 48 h after seeding, and exposed to CPT 24 h before (-24 h), during (0 h),
or 24 h after (+24 h) CPT exposure. Treatment controls included no treatment
(NT), and CPT exposure alone at the respective time points. Treatment groups
were analyzed for viability 48 h post transfection.
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Figure 12: The effect of surface modification on particle size.
Scanning electron microscopy (SEM) images of multi-layered nanoparticles
during surface modification. A. Non-modified poly(lactic-co-glycolic) acid (PLGA)
nanoparticles. B. PLGA nanoparticles with surface polyethyleneimine (PEI) and
plasmid DNA (PLGA-PD). C. PLGA-PD particles modified with a second layer of
PEI (PLGA-PDP. D. PLGA-PDP particles modified with a heterobifunctional
polyethylene glycol (PEG) linker (PLGA-PDP-PEG). E. PLGA-PDP-PEG particles
conjugated to modified antennapedia (PLGA-PDP-PEG-mAP). F. Dry particle
diameters measured from SEM images. Figure 12A contains a different length
scale.
Figure 13: The effect of surface modifications on particle surface charge
and polyethyleneimine loading.
The surface charge and polyethyleneimine (PEI) load of multi-layered
nanoparticles during surface modification. A. Non-modified poly(lactic-co-glycolic)
acid (PLGA) nanoparticles. B. PLGA nanoparticles with surface PEI (PLGA-P).
C. PLGA-P particles complexed with plasmid DNA (PLGA-PD). D. PLGA-PD
modified with a second layer of PEI (PLGA-PDP). E. PLGA-PDP particles
modified with a heterobifunctional polyethylene glycol (PEG) linker (PLGA-PDPPEG). F. PLGA-PDP-PEG particles surface conjugated with modified
antennapedia (PLGA-PDP-PEG-mAP).
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Figure 14: The effect of surface modifications on particle toxicity.
Toxicity of multi-layered nanoparticles after surface modification. A. Poly(lacticco-glycolic) acid (PLGA) nanoparticles with surface polyethyleneimine (PEI) and
plasmid DNA (PLGA-PD). B. PLGA-PD particles with a second layer of PEI
(PLGA-PDP). C. PLGA-PDP particles modified with a heterobifunctional
polyethylene glycol (PEG) linker attached to modified antennapedia (PLGA-PDPPEG-mAP). D. Lipofectamine particles. PLGA-PDP-PEG-mAP particles were
significantly less toxic than the other particles.
Figure 15: Particle release profiles.
Camptothecin (CPT), polyethyleneimine (PEI), and plasmid release from nonmodified nanoparticles and multi-layered nanoparticles (MLNPs). Surface
modification did not affect CPT release. Approximately 80% of total CPT was
released in 12-24 h, while approximately 80% of total plasmid was released
between 24-48 h.
Figure 16: Population transfection optimization.
Optimizing multi-layered nanoparticles (MLNPs) for transfecting 293T cells.
MLNPs were loaded with a plasmid encoding for luciferase. A. The effect of
surface modification on particle transfection. B. The effect of decreasing the size
of the polyethylene glycol (PEG) linker, changing the organic solvent during
fabrication, and encapsulating trans-1,2-cyclohexanediol (TCHD) within the
poly(lactic-co-glycolic) acid (PLGA) core on particle transfection. C. The effect of
initial seeding density on particle transfection. EA – ethyl acetate, DCM –
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dichloromethane, PLGA-PD - PLGA nanoparticles with surface PEI and plasmid
DNA), PLGA-PDP - PLGA-PD modified with a second layer of PEI, PLGA-PDPPEG-mAP - PLGA-PDP particles modified with a heterobifunctional polyethylene
glycol (PEG) linker attached to modified antennapedia.
Figure 17: Green fluorescent protein expression after particle transfection.
Confocal fluorescent imaging of 293T cells transfected with multi-layered
nanoparticles (MLNPs) or lipofectamine particles carrying plasmid encoding for
green fluorescent protein (GFP). A-B. 293T cells transfected with MLNPs after 48
h and 72 h respectively. C-D. 293T cells transfected with lipofectamine after 48 h
and 72 h respectively.
Figure 18: Percent cell transfection.
Fluorescence-activated cell sorting (FACS) of 293T cells transfected with multilayered nanoparticles (MLNPs) or lipofectamine particles carrying plasmid
encoding green fluorescent protein (GFP). Fluorescence measured via the FL1-H
channel detected transfected cells. After 72 h, approximately 37% of cells were
transfected by MLNPs and 58% of cells were transfected by lipofectamine.
Figure 19: Tumor death kinetics relative to camptothecin exposure and
transfection with plasmid encoding for TNF related apoptosis inducing
ligand.
Death kinetics of A. U87, B. HCT116, and C. MDAMB231 cells related to
camptothecin (CPT) exposure and TNF related apoptosis inducing ligand
(TRAIL) plasmid transfection. Cells were exposed to CPT 24 h before, during (0
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h), or 24 h after transfection. Relative growth inhibition was determined by
normalizing cell viability after combined treatments to cells exposed to CPT only
at respective time points.
Figure 20: The effect of multi-layered nanoparticle loading and cell death.
Cell viability 72 h after exposure to multi-layered nanoparticles (MLNPs) loaded
with decreasing camptothecin (CPT) relative to TRAIL plasmid (pTRAIL).
HCT116 cells were exposed to MLNPs loaded with CPT to pTRAIL ratios of 5,
0.03, and 0.01 (CT1, CT2, and CT3 respectively). Treatment with CT2 MLNP
resulted in significantly lower cell proliferation.
Figure 21: Dose Effect curves.
The fraction affected (Fa), in terms of cell death, related to camptothecin (CPT)
and TRAIL plasmid (pTRAIL) dosing as delivered by different nanoparticle
systems. A. Tumor cells were exposed to multi-layered nanoparticles (MLNPs)
delivering CPT and a plasmid encoding for luciferase (CL2 MLNP), and MLNPs
delivering CPT and pTRAIL (CT2 MLNPs). B. Tumor cells were exposed to CT2
MLNPs and poly(lactic-co-glycolic) (PLGA) nanoparticles encapsulating CPT only
(CPT NPs). C. Tumor cells were exposed to MLNPs containing only pTRAIL (BT
MLNPs) or CT2 MLNPs. All MLNPs were loaded with the same amount of
plasmid and the same CPT to pTRAIL ratio of 0.03.
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Figure 22: Chou-Talalay synergism analysis of CT2 MLNPs compared to
CL2 MLNPs and BT MLNPs.
The Chou-Talalay analysis of the dose effect curves determined in Figure 21.
Combination index (CI) values for multi-layered nanoparticles (MLNPs) delivering
CPT and plasmid encoding TNF related apoptosis inducing ligand (pTRAIL) (CT2
MLNPs), and the CPT and pTRAIL dose-reduction index of CT2 MLNPs relative
to MLNPs delivering CPT and a plasmid encoding for luciferase (CL2 MLNP) and
MLNPs containing only pTRAIL (BT MLNPs). The theoretical values were those
determined by the Chou-Talalay analysis model for all fraction affected (Fa)
levels, and the experimental values were those determined for actual CT2 MLNP
doses. All MLNPs were loaded with the same amount of plasmid and the same
CPT to pTRAIL ratio of 0.03.
Figure 23: Chou-Talalay synergism analysis of CT2 MLNPs compared to
CPT NPs and BT MLNPs.
The Chou-Talalay analysis of the dose effect curves determined in Figure 21.
Combination index (CI) values for multi-layered nanoparticles (MLNPs) delivering
CPT and plasmid encoding TNF related apoptosis inducing ligand (pTRAIL) (CT2
MLNPs), and the CPT and pTRAIL dose-reduction index of CT2 MLNPs relative
to poly(lactic-co-glycolic) (PLGA) nanoparticles encapsulating CPT only (CPT
NPs) and MLNPs containing only pTRAIL (BT MLNPs). The theoretical values
were those determined by the Chou-Talalay analysis model for all fraction
affected (Fa) levels, and the experimental values were those determined for
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actual CT2 MLNP doses. All MLNPs were loaded with the same amount of
plasmid and the same CPT to pTRAIL ratio of 0.03.
Figure 24: in vivo antitumor effects of MLNPs.
The tumor growth curve for HCT116 xenografts in mice receiving treatments with
MLNPs. This is the initial growth response shows a greater inhibition of tumor
growth for mice receiving CT2 MLNPs and BT MLNPs.

8 Tables
Table 1: Hallmarks of cancer pathogenesis and therapeutic implications.
The cellular and molecular alterations responsible for the multiple hallmarks of
cancer pathogenesis as described by Hanahan et al7 and related targeted
therapies. Bax - Bcl-2-associated X, Bcl - B-cell lymphoma, BRCA – breast
cancer, CCL5/RANTES - Chemokine (C-C motif) ligand 5/ regulated on
activation, normal T cell expressed and secreted, CCPs - cysteine cathepsin
proteases, CD4 – cluster of differentiation 4, CSF – colony-stimulating factor,
CTL - CD8+ cytotoxic T lymphocytes, EMT - epithelial-mesenchymal transition,
EPH – ephrin type, FGF - fibroblast growth factor, GLUT – glucose transporter,
HGF – hepatocyte growth factor, HIF – hypoxia-inducible factor, IDH - isocitrate
dehydrogenase, IL – interleukin, LKB1 – liver kinase B1, MAP – mitogenactivated protein, MCL – myeloid cell leukemia, MDSCs - myeloid-derived
suppressor cells, mTOR – mammalian target of rapamycin, NF2 – neurofibromin
2 (merlin), NK – natural killer, PI3 - Phosphatidylinositide 3, PTEN – phosphatase
and tensin homolog, RB – retinoblastoma, Robo – roundabout, TGF –
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transforming growth factor, Th – T helper, Tregs - regulatory T cells, TSP –
thrombospondin, VEGF – vascular endothelial growth factor, ZEB - Zinc finger Ebox-binding homeobox.
Table 2: Examples of nanoparticle therapeutics.
Examples of nanocarriers and specific formulations that are being clinically
evaluated for treating cancer. PLA – Polylactic acid, tSVPTM – targeted
Synthetic Vaccine Particle.
Table 3: Lipophilicity of common anti-neoplastic agents.
The distribution coefficients (D) of clinically available anti-neoplastic agents
organized by class.
Table 4: Methods of gene delivery56,58,78,79,81,82.
Methods for gene delivery. There are multiple categories of delivery methods for
genetic material. Specific gene delivery systems within each class, and the
associated transfection efficiencies and toxicities for each modality are provided.
I-low, II-medium, III-high, GALA- glutamic acid-alanine-leucine-alanine, KALAlysine-alanine-leucine-alanine, PAMAM-polyamidoamine, PbAE- poly(beta-amino
ester), PEI-Polyethyleneimine, PLA-polylactic acid, PLGA- poly(lactic-co-glycolic
acid).
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Table 5: Strategies for addressing gene delivery barriers via nanoparticles.
Nanoparticle technology can address the multiple barriers (Figure 7) for gene
delivery. Common techniques to address the six major barriers are provided.
NLS – Nuclear localization signal, TCHD - trans-cyclohexane-1,2-diol.
Table 6: Evaluation of Combination Index values125,126.
The combination index (CI) values obtained from the Chou-Talalay analysis can
predict synergistic, additive, or antagonistic interactions. Values less than one
suggest a synergistic interaction, and values greater than one suggest an
antagonistic interaction. CI values close to one are indicative of an additive
response.
Table 7: Particle characteristics.
Physical characteristics of multi-layered nanoparticles. Dry and hydrodynamic
particle diameter as measured by scanning electron micrograph (SEM) and
dynamic light scattering (Zeta), surface charge, polyethyleneimine (PEI) loading,
and plasmid loading for each particle formulation are provided.
Table 8: Camptothecin encapsulation.
Camptothecin (CPT) encapsulation and loading efficiency for multi-layered
nanoparticles (MLNPs). MLNPs were initially loaded with 0.1, 0.001, or 0.0001
mg CPT per mg polymer (CT1, CT2, CT3 respectively).
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Table 9: Camptothecin to TNF related apoptosis inducing ligand ratio.
The camptothecin (CPT) to TNF related apoptosis inducing ligand (TRAIL) ratios
for the treatment groups analyzed in the death kinetics experiments (Figure 19).
Table 10: Camptothecin to TNF related apoptosis inducing ligand ratio for
multi-layered nanoparticle formulations.
The camptothecin (CPT) to TNF related apoptosis inducing ligand (TRAIL)
loading ratios for the multi-layered nanoparticles analyzed in Figure 20. These
particles are the same formulations analyzed in Table 8.
Table 11: Goodness of fit of the Chou-Talalay analysis.
The linear regression coefficients for fitting the dose effect curves (Figure 21) to
the median effect equation (MEE) transformation (Equation 2). The coefficients
were greater than 0.90 for all dose effect curves indicating that the MEE is a
good model.
Table 12: Combination index, dose-reduction index, and median effect
dose, for CT2 MLNPs and CL2 MLNPs.
The combination index (CI), dose-reduction index (DRI), and the median effect
dose (Dm) for the different nanoparticle formulations. Dm is the dose of CPT
required to obtain a Fa level of 0.50. Multi-layered nanoparticles (MLNPs)
delivering camptothecin (CPT) and TNF related apoptosis inducing ligand
plasmid (CT2 MLNP) were compared to MLNPs delivering CPT and a plasmid
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encoding for luciferase (CL2 MLNPs). All MLNPs were loaded with the same
amount of plasmid and the same CPT to pTRAIL ratio of 0.03.
Table 13: Combination index, dose-reduction index, and median effect dose
for CT2 MLNPs and CPT NPs.
The combination index (CI), dose-reduction index (DRI), and the median effect
dose (Dm) for the different nanoparticle formulations. Dm is the dose of CPT
required to obtain a Fa level of 0.50. Multi-layered nanoparticles (MLNPs)
delivering camptothecin (CPT) and TNF related apoptosis inducing ligand
plasmid (CT2 MLNP) were compared to poly(lactic-co-glycolic) acid
nanoparticles containing only CPT (CPT NPs). The MLNPs were loaded with a
CPT to pTRAIL ratio of 0.03.

